BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, Vlachojannis GJ, Jensen LO, Christiansen EH, Berencsi K. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. J Am Coll Cardiol. 2015;65:2496-2507. [PMID: 26065988 DOI: 10.1016/j.jacc.2015.04.017] [Cited by in Crossref: 325] [Cited by in F6Publishing: 275] [Article Influence: 46.4] [Reference Citation Analysis]
Number Citing Articles
1 Giustino G, Dangas GD. Bioresorbable Vascular Scaffolds in Women. JACC Cardiovasc Interv 2017;10:1891-3. [PMID: 28935082 DOI: 10.1016/j.jcin.2017.08.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Krackhardt F, Rosli MA, Leschke M, Schneider A, Sperling C, Heang TM, Pons M, Sousa PJ, Kherad B, Waliszewski M. Propensity score matched all comers population treated with ultra-thin strut bare metal and sirolimus-probucol coated drug-eluting stents of identical stent architecture. Catheter Cardiovasc Interv 2018;91:1221-8. [PMID: 28944613 DOI: 10.1002/ccd.27306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Moreno R, Legrand V, Ferrario M, MacCarthy P, Redwood S, Werner N, Jung W, Ungi I, Zaman A, Richardt G, Crowley J, Schwimmbeck P, Christen T, Allocco DJ, Meredith IT. Clinical outcomes in unselected patients treated with the PROMUS Element platinum-chromium, everolimus-eluting stent: Final five-year results from the PE PROVE Study. Catheter Cardiovasc Interv 2019;93:398-403. [PMID: 30341836 DOI: 10.1002/ccd.27835] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Tanaka A, Jabbour RJ, Mitomo S, Latib A, Colombo A. Hybrid Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffolds in Combination With Drug-Eluting Stents or Drug-Coated Balloons for Complex Coronary Lesions. JACC Cardiovasc Interv. 2017;10:539-547. [PMID: 28335892 DOI: 10.1016/j.jcin.2016.12.285] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
5 Torii S, Jinnouchi H, Sakamoto A, Mori H, Park J, Amoa FC, Sawan M, Sato Y, Cornelissen A, Kuntz SH, Kutyna M, Paek KH, Fernandez R, Braumann R, Mont EK, Surve D, Romero ME, Kolodgie FD, Virmani R, Finn AV. Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing. Eur Heart J 2020;41:786-96. [PMID: 31803916 DOI: 10.1093/eurheartj/ehz850] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
6 van Bommel RJ, Lemmert ME, van Mieghem NM, van Geuns R, van Domburg RT, Daemen J. Occurrence and predictors of acute stent recoil-A comparison between the xience prime cobalt chromium stent and the promus premier platinum chromium stent: Acute Recoil in Xience Prime and Promus Premier. Catheter Cardiovasc Interv 2018;91:E21-8. [DOI: 10.1002/ccd.27096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
7 Guedeney P, Claessen BE, Mehran R, Mintz GS, Liu M, Sorrentino S, Giustino G, Farhan S, Leon MB, Serruys PW, Smits PC, von Birgelen C, Ali ZA, Généreux P, Redfors B, Madhavan MV, Ben-yehuda O, Stone GW. Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation. JACC: Cardiovascular Interventions 2020;13:1417-28. [DOI: 10.1016/j.jcin.2020.03.053] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
8 Kitabata H, Kubo T, Mori K, Yamamoto Y, Kashiwagi M, Arita Y, Tanimoto T, Akasaka T. Safety and efficacy outcomes of second-generation everolimus-eluting stents in octogenarians compared to non-octogenarians. Cardiovascular Revascularization Medicine 2018;19:12-6. [DOI: 10.1016/j.carrev.2017.05.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Feldman DA, Shroff AR, Bao H, Curtis JP, Minges KE, Ardati AK. Stent selection among patients with chronic kidney disease: Results from the NCDR CathPCI Registry. Catheter Cardiovasc Interv 2020;96:1213-21. [PMID: 31909543 DOI: 10.1002/ccd.28698] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Wong W, Lai CN, Cheng W, Tung L, Chang RC, Leung FK. Polymer–Metal Composite Healthcare Materials: From Nano to Device Scale. J Compos Sci 2022;6:218. [DOI: 10.3390/jcs6080218] [Reference Citation Analysis]
11 Lansky A, Chun H, Pietras C, Hussain Y. Refining drug-eluting stent technologies: from engineering to basic science. Eur Heart J 2021;42:1770-2. [PMID: 33624813 DOI: 10.1093/eurheartj/ehab091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Torii S, Jinnouchi H, Sakamoto A, Kutyna M, Cornelissen A, Kuntz S, Guo L, Mori H, Harari E, Paek KH, Fernandez R, Chahal D, Romero ME, Kolodgie FD, Gupta A, Virmani R, Finn AV. Drug-eluting coronary stents: insights from preclinical and pathology studies. Nat Rev Cardiol 2020;17:37-51. [DOI: 10.1038/s41569-019-0234-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
13 Park H, Kang DY, Kim SO, Lee J, Kim JH, Hyun J, Lee PH, Ahn JM, Park SJ, Park DW; MAIN-COMPARE Investigators. Ten-year outcomes of early generation sirolimus- versus paclitaxel-eluting stents in patients with left main coronary artery disease. Catheter Cardiovasc Interv 2021;98:E705-14. [PMID: 34420257 DOI: 10.1002/ccd.29930] [Reference Citation Analysis]
14 Henriques JPS, Elias J. The first generation ABSORB BVS scaffold; to be or not to be? Neth Heart J 2017;25:416-8. [PMID: 28643296 DOI: 10.1007/s12471-017-1007-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
15 Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, Bonnet G, Fourcade L, Mouret JP, Lambert M, Verdier V, Morange PE, Alessi MC, Bonnet JL. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38:3070-3078. [PMID: 28510646 DOI: 10.1093/eurheartj/ehx175] [Cited by in Crossref: 175] [Cited by in F6Publishing: 135] [Article Influence: 43.8] [Reference Citation Analysis]
16 Bertaina M, De Filippo O, Iannaccone M, Colombo A, Stone G, Serruys P, Mancone M, Omedè P, Conrotto F, Pennone M, Kimura T, Kawamoto H, Zoccai GB, Sheiban I, Templin C, Benedetto U, Cavalcante R, D’amico M, Gaudino M, Moretti C, Gaita F, D’ascenzo F. Percutaneous coronary intervention or coronary artery bypass graft in left main coronary artery disease: a comprehensive meta-analysis of adjusted observational studies and randomized controlled trials. Journal of Cardiovascular Medicine 2018;19:554-63. [DOI: 10.2459/jcm.0000000000000703] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
17 Sousa-uva M, Neumann F, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferović PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, Wijns W, Glineur D, Aboyans V, Achenbach S, Agewall S, Andreotti F, Barbato E, Baumbach A, Brophy J, Bueno H, Calvert PA, Capodanno D, Davierwala PM, Delgado V, Dudek D, Freemantle N, Funck-brentano C, Gaemperli O, Gielen S, Gilard M, Gorenek B, Haasenritter J, Haude M, Ibanez B, Iung B, Jeppsson A, Katritsis D, Knuuti J, Kolh P, Leite-moreira A, Lund LH, Maisano F, Mehilli J, Metzler B, Montalescot G, Pagano D, Petronio AS, Piepoli MF, Popescu BA, Sádaba R, Shlyakhto E, Silber S, Simpson IA, Sparv D, Tavilla G, Thiele H, Tousek P, Van Belle E, Vranckx P, Witkowski A, Zamorano JL, Roffi M, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet J, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, Mcdonagh TA, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Sousa-uva M, Simpson IA, Zamorano JL, Pagano D, Freemantle N, Sousa-uva M, Chettibi M, Sisakian H, Metzler B, İbrahimov F, Stelmashok VI, Postadzhiyan A, Skoric B, Eftychiou C, Kala P, Terkelsen CJ, Magdy A, Eha J, Niemelä M, Kedev S, Motreff P, Aladashvili A, Mehilli J, Kanakakis I, Becker D, Gudnason T, Peace A, Romeo F, Bajraktari G, Kerimkulova A, Rudzītis A, Ghazzal Z, Kibarskis A, Pereira B, Xuereb RG, Hofma SH, Steigen TK, Witkowski A, de Oliveira EI, Mot S, Duplyakov D, Zavatta M, Beleslin B, Kovar F, Bunc M, Ojeda S, Witt N, Jeger R, Addad F, Akdemir R, Parkhomenko A, Henderson R; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-Thoracic Surgery 2019;55:4-90. [DOI: 10.1093/ejcts/ezy289] [Cited by in Crossref: 208] [Cited by in F6Publishing: 154] [Article Influence: 52.0] [Reference Citation Analysis]
18 Omar WA, Kumbhani DJ. The Current Literature on Bioabsorbable Stents: a Review. Curr Atheroscler Rep 2019;21. [DOI: 10.1007/s11883-019-0816-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
19 Zhu Z, Zhu J, Du R, Zhang H, Ni J, Quan W, Hu J, Ding F, Yang Z, Zhang R. Efficacy of Zotarolimus-Eluting Stents in Treating Diabetic Coronary Lesions: An Optical Coherence Tomography Study. Adv Ther 2020;37:1579-90. [PMID: 32146703 DOI: 10.1007/s12325-020-01273-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Mori H, Otsuka F, Gupta A, Jinnouchi H, Torii S, Harari E, Virmani R, Finn AV. Revisiting the role of durable polymers in cardiovascular devices. Expert Review of Cardiovascular Therapy 2017;15:835-46. [DOI: 10.1080/14779072.2017.1386098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
21 Wang B, Hua J, You R, Yan K, Ma L. Electrochemically deposition of catechol-chitosan hydrogel coating on coronary stent with robust copper ions immobilization capability and improved interfacial biological activity. Int J Biol Macromol 2021;181:435-43. [PMID: 33781813 DOI: 10.1016/j.ijbiomac.2021.03.158] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Cui KY, Lyu SZ, Zhang M, Song XT, Yuan F, Xu F. Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis: An Updated Systematic Review and Meta-Analysis. Chin Med J (Engl) 2018;131:600-7. [PMID: 29483397 DOI: 10.4103/0366-6999.226073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
23 Hansen KW, Jeger R, Sørensen R, Kaiser C, Pfisterer M, Biering-Sørensen T, Bjerking LH, Galatius S. Do ultrathin strut bare-metal stents with passive coating improve efficacy in large coronary arteries? Insights from the randomized, multicenter BASKET-PROVE trials. BMC Cardiovasc Disord 2019;19:226. [PMID: 31619181 DOI: 10.1186/s12872-019-1199-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Sinha N, Rai H, Cassese S, Kumar S, Kapoor A, Kastrati A. Long-term clinical impact of polymer-free sirolimus-eluting stents in unselected patients. Coron Artery Dis 2016;27:385-90. [PMID: 27124380 DOI: 10.1097/MCA.0000000000000378] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Shah R, Rao SV, Latham SB, Kandzari DE. Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy: A Meta-analysis. JAMA Cardiol 2018;3:1050-9. [PMID: 30383145 DOI: 10.1001/jamacardio.2018.3551] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
26 Loh JP, Poh KK. Changes in the practice of cardiology: therapies at the forefront of science. Singapore Med J 2016;57:344-6. [PMID: 27440236 DOI: 10.11622/smedj.2016115] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Wu SW, Pan Q, Chen T, Wei LY, Xuan Y, Wang Q, Li C, Song JC. Research of Medical Expenditure among Inpatients with Unstable Angina Pectoris in a Single Center. Chin Med J (Engl) 2017;130:1529-33. [PMID: 28639566 DOI: 10.4103/0366-6999.208242] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Verdoia M, Khedi E, Suryapranata H, De Luca G. Tratamiento antiagregante de muy corta duración tras la ICP y nuevos SLF: metanálisis de 5 estudios aleatorizados. Revista Española de Cardiología 2021;74:140-8. [DOI: 10.1016/j.recesp.2020.03.013] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
29 Mahmoud KD, Zijlstra F. Thrombus aspiration in acute myocardial infarction. Nat Rev Cardiol 2016;13:418-28. [DOI: 10.1038/nrcardio.2016.38] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
30 Kwon O, Kang SH, Lee J, Ahn J, Lee CH, Kang D, Lee PH, Kang S, Lee S, Kim Y, Lee CW, Park S, Park D, Park S. Comparative effectiveness of different contemporary drug-eluting stents in routine clinical practice: a multigroup propensity score analysis using data from the stent-specific, multicenter, prospective registries. Coronary Artery Disease 2019;30:255-62. [DOI: 10.1097/mca.0000000000000730] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Qian F, Zhong Y, Hannan EL. Four-year comparative effectiveness of bare-metal and everolimus-eluting stents in New York. Catheter Cardiovasc Interv 2018;91:417-24. [PMID: 28557275 DOI: 10.1002/ccd.27144] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Bavishi C, Trivedi V, Singh M, Katz E, Messerli FH, Bangalore S. Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Am J Med 2017;130:1325.e1-1325.e12. [PMID: 28623176 DOI: 10.1016/j.amjmed.2017.05.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
33 Summaria F, Sgueglia GA, D'Errico F, De Santis A, Piccioni F, Gioffrè G, Gaspardone A. Safety and Efficacy of Triple Therapeutic Targets with Rivaroxaban after Acute Myocardial Infarction Complicated by Left Ventricular Thrombi in a Case of Nonvalvular Atrial Fibrillation. Case Rep Cardiol 2018;2018:6503435. [PMID: 29692936 DOI: 10.1155/2018/6503435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Tomberli B, Mattesini A, Baldereschi GI, Di Mario C. A Brief History of Coronary Artery Stents. Rev Esp Cardiol (Engl Ed) 2018;71:312-9. [PMID: 29361499 DOI: 10.1016/j.rec.2017.11.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
35 Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopczuk J, Moreno R, Choudhury A, Petrov I, Cequier A, Kukreja N, Hoye A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S, Tonev G, Mathur A, Merkely B, Colombo A, Ijsselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. The Lancet 2019;393:987-97. [DOI: 10.1016/s0140-6736(18)32467-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 12] [Article Influence: 12.3] [Reference Citation Analysis]
36 Rosol Z, Vasudevan A, Sawhney R, Hebeler RF, Tecson KM, Stoler RC. Hybrid intervention approach to coronary artery and valvular heart disease. Proc (Bayl Univ Med Cent) 2020;33:520-3. [PMID: 33100519 DOI: 10.1080/08998280.2020.1784638] [Reference Citation Analysis]
37 Sharma A, Garg A, Elmariah S, Drachman D, Obiagwu C, Vallakati A, Sharma SK, Lavie CJ, Mukherjee D, Waksman R, Stefanini GG, Feres F, Marmur JD, Helft G. Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Prog Cardiovasc Dis 2018;60:500-7. [PMID: 29277295 DOI: 10.1016/j.pcad.2017.12.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
38 Milojevic M, Milacic P, Petrovic I, Bojic M, Milojevic A, Nikolic A, Sandner S, Sousa-Uva M. Mapping decision making for bypass surgery in the era of interventional medicine: towards an integrative model of patient-centeredness. Minerva Cardioangiol 2020;68:469-79. [PMID: 32657555 DOI: 10.23736/S0026-4725.20.05228-7] [Reference Citation Analysis]
39 Lee YJ, Cho JY, Yun KH, Lee SJ, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, Jang Y, Kim JS. Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial. EuroIntervention 2022:EIJ-D-22-00135. [PMID: 35470799 DOI: 10.4244/EIJ-D-22-00135] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Lu DY, Steitieh D, Feldman DN, Cheung JW, Wong SC, Halazun H, Halazun KJ, Amin N, Wang J, Chae J, Wilensky RL, Kim LK. Impact Of Cirrhosis On 90-Day Outcomes After Percutaneous Coronary Intervention (from A Nationwide Database). Am J Cardiol 2020;125:1295-304. [PMID: 32145896 DOI: 10.1016/j.amjcard.2020.01.052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
41 Lansky AJ, Kereiakes DJ, Baumbach A, Windecker S, Hussain Y, Pietras C, Dressler O, Issever O, Curtis M, Bertolet B, Zidar JP, Smits PC, Alfonso Jiménez Díaz V, McLaurin B, Hofma S, Cequier Á, Dib N, Benit E, Mathur A, Brogno D, Berland J, Wykrzykowska J, Piegari G, Brugaletta S, Saito S, Leon MB; PIONEER III Trial Investigators. Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial. Circulation 2021;143:2143-54. [PMID: 33820424 DOI: 10.1161/CIRCULATIONAHA.120.052482] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Cai JZ, Zhu YX, Wang XY, Bourantas CV, Iqbal J, Zhu H, Cummins P, Dong SJ, Mathur A, Zhang YJ. Comparison of new-generation drug-eluting stents versus drug-coated balloon for in-stent restenosis: a meta-analysis of randomised controlled trials. BMJ Open 2018;8:e017231. [PMID: 29472254 DOI: 10.1136/bmjopen-2017-017231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
43 Ferenc M, Gick M, Comberg T, Rothe J, Valina C, Toma A, Löffelhardt N, Hochholzer W, Riede F, Kienzle R, Achtari A, Neumann F. Culotte stenting vs. TAP stenting for treatment of de-novo coronary bifurcation lesions with the need for side-branch stenting: the Bifurcations Bad Krozingen (BBK) II angiographic trial. Eur Heart J 2016;37:3399-405. [DOI: 10.1093/eurheartj/ehw345] [Cited by in Crossref: 39] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
44 Byrne RA, Schuster T. Biodegradable polymer drug-eluting stents: caveat emptor. Lancet 2017;390:1814-6. [PMID: 29082870 DOI: 10.1016/S0140-6736(17)32668-5] [Reference Citation Analysis]
45 Dangas GD, Claessen BE. Stent Technology Reaches Maturity? JACC Cardiovasc Interv 2020;13:2879-81. [PMID: 33357525 DOI: 10.1016/j.jcin.2020.10.004] [Reference Citation Analysis]
46 Wu X, Wu S, Kawashima H, Hara H, Ono M, Gao C, Wang R, Lunardi M, Sharif F, Wijns W, Serruys PW, Onuma Y. Current perspectives on bioresorbable scaffolds in coronary intervention and other fields. Expert Rev Med Devices 2021;18:351-65. [PMID: 33739213 DOI: 10.1080/17434440.2021.1904894] [Reference Citation Analysis]
47 Kimura T, Saito S, Ando K, Ito Y, Kozuma K, Yajima J, Nakamura M, Hagiwara N, Yasuda S, Fukamachi D, Shinke T, Ueno T, Allocco DJ. Final 5-Year Results in Randomized Japanese Patients Implanted With a Thin-Strut, Bioabsorbable, Polymer-Coated, Everolimus-Eluting SYNERGY Stent (From the EVOLVE II Study). Circ Rep 2020;3:9-17. [PMID: 33693285 DOI: 10.1253/circrep.CR-20-0114] [Reference Citation Analysis]
48 Kandzari DE, Amjadi N, Caputo C, Rowe SK, Williams J, Tamboli HP, Christen T, Allocco DJ, Dawkins KD. One-Year Outcomes in "Real-World" Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS]). Am J Cardiol 2016;117:539-45. [PMID: 26732420 DOI: 10.1016/j.amjcard.2015.11.043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
49 Taxiarchi P, Martin GP, Kinnaird T, Curzen N, Ahmed J, Ludman P, De Belder M, Shoaib A, Rashid M, Kontopantelis E, Mamas MA. Contributors to the Growth of Same Day Discharge After Elective Percutaneous Coronary Intervention. Circ: Cardiovascular Interventions 2020;13. [DOI: 10.1161/circinterventions.119.008458] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Taxiarchi P, Kontopantelis E, Martin GP, Kinnaird T, Curzen N, Banning AP, Ludman P, De Belder M, Rashid M, Sperrin M, Mamas MA. Same-Day Discharge After Elective Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 2019;12:1479-94. [DOI: 10.1016/j.jcin.2019.03.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
51 Dalal A. Organ transplantation and drug eluting stents: Perioperative challenges. World J Transplant 2016; 6(4): 620-631 [PMID: 28058211 DOI: 10.5500/wjt.v6.i4.620] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
52 Torii S, Kolodgie FD, Virmani R, Finn AV. IN.PACT™ Admiral™ drug-coated balloons in peripheral artery disease: current perspectives. Med Devices (Auckl) 2019;12:53-64. [PMID: 30858737 DOI: 10.2147/MDER.S165620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
53 Cui K, Zhang D, Lyu S, Song X, Yuan F, Xu F, Zhang M. Meta-Analysis Comparing Percutaneous Coronary Revascularization Using Drug-Eluting Stent Versus Coronary Artery Bypass Grafting in Patients With Left Ventricular Systolic Dysfunction. Am J Cardiol 2018;122:1670-6. [PMID: 30220418 DOI: 10.1016/j.amjcard.2018.08.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
54 Franzone A, Zaugg S, Piccolo R, Modena MG, Mikhail GW, Ferré JM, Strasser R, Grinfeld L, Heg D, Jüni P, Windecker S, Morice MC. A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study. PLoS One 2017;12:e0182632. [PMID: 28796809 DOI: 10.1371/journal.pone.0182632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
55 Ielasi A, Buono A, Pellicano M, Tedeschi D, Loffi M, Donahue M, Regazzoli D, De Angelis G, Danzi G, Reimers B, Tespili M. A HYbrid APproach Evaluating a DRug-Coated Balloon in Combination With a New-Generation Drug-Eluting Stent in the Treatment of De Novo Diffuse Coronary Artery Disease: The HYPER Pilot Study. Cardiovasc Revasc Med 2021;28:14-9. [PMID: 32933874 DOI: 10.1016/j.carrev.2020.07.036] [Reference Citation Analysis]
56 Prado GFA Jr, Abizaid AAC, Meireles GC, Sarmento-Leite R, Prudente M, Cantarelli M, Dourado AD, Jr JM, Perin MA, Costantini C, Costa R, Costa JR, Chamie D, Campos CM, Ribeiro EE, Lemos PA. Comparative clinical performance of two types of drug-eluting stents with abluminal biodegradable polymer coating: Five-year results of the DESTINY randomized trial. Rev Port Cardiol (Engl Ed) 2021;40:71-6. [PMID: 33402278 DOI: 10.1016/j.repc.2020.05.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Basaraba JE, Barry AR. What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation? Am J Health Syst Pharm 2016;73:e229-37. [PMID: 27099329 DOI: 10.2146/ajhp150655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
58 Kereiakes DJ, Ellis SG, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, Tan SH, Ediebah DE, Simonton C, Stone GW; ABSORB III Investigators. Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial. Circulation. 2019;140:1895-1903. [PMID: 31553222 DOI: 10.1161/circulationaha.119.042584] [Cited by in Crossref: 26] [Cited by in F6Publishing: 8] [Article Influence: 8.7] [Reference Citation Analysis]
59 Cui KY, Lyu SZ, Song XT, Yuan F, Xu F, Zhang M, Zhang MD, Wang W, Zhang DF, Dai J, Tian JF, Wang YL. Long term outcomes of drug-eluting stent versus coronary artery bypass grafting for left main coronary artery disease: a meta-analysis. J Geriatr Cardiol 2018;15:162-72. [PMID: 29662510 DOI: 10.11909/j.issn.1671-5411.2018.02.009] [Reference Citation Analysis]
60 Cui K, Lyu S, Song X, Yuan F, Xu F, Zhang M, Wang W, Zhang D, Dai J. Drug-eluting balloon versus bare-mental stent and drug-eluting stent for de novo coronary artery disease: A systematic review and meta-analysis of 14 randomized controlled trials. PLoS One 2017;12:e0176365. [PMID: 28445555 DOI: 10.1371/journal.pone.0176365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
61 Qiu H, Qi P, Liu J, Yang Y, Tan X, Xiao Y, Maitz MF, Huang N, Yang Z. Biomimetic engineering endothelium-like coating on cardiovascular stent through heparin and nitric oxide-generating compound synergistic modification strategy. Biomaterials 2019;207:10-22. [PMID: 30947118 DOI: 10.1016/j.biomaterials.2019.03.033] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
62 Zocca P, Kok MM, van der Heijden LC, van Houwelingen KG, Hartmann M, de Man FH, Stoel MG, Louwerenburg JW, Knottnerus IL, Linssen GC, Doggen CJ, von Birgelen C. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT. International Journal of Cardiology 2018;268:11-7. [DOI: 10.1016/j.ijcard.2018.03.116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
63 Conway C, Nezami FR, Rogers C, Groothuis A, Squire JC, Edelman ER. Acute Stent-Induced Endothelial Denudation: Biomechanical Predictors of Vascular Injury. Front Cardiovasc Med 2021;8:733605. [PMID: 34722666 DOI: 10.3389/fcvm.2021.733605] [Reference Citation Analysis]
64 Mahmoud AN, Barakat AF, Elgendy AY, Schneibel E, Mentias A, Abuzaid A, Elgendy IY. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials. Circ Cardiovasc Interv. 2017;10:pii: e005286. [PMID: 28468954 DOI: 10.1161/circinterventions.117.005286] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
65 Go YI, Kim GW. Bilateral multifocal muscular hemorrhage in the triceps surae during antiplatelet therapy: a case report. J Int Med Res 2021;49:3000605211064391. [PMID: 34936520 DOI: 10.1177/03000605211064391] [Reference Citation Analysis]
66 Escaned J, Collet C, Ryan N, De Maria GL, Walsh S, Sabate M, Davies J, Lesiak M, Moreno R, Cruz-Gonzalez I, Hoole SP, Ej West N, Piek JJ, Zaman A, Fath-Ordoubadi F, Stables RH, Appleby C, van Mieghem N, van Geuns RJ, Uren N, Zueco J, Buszman P, Iñiguez A, Goicolea J, Hildick-Smith D, Ochala A, Dudek D, Hanratty C, Cavalcante R, Kappetein AP, Taggart DP, van Es GA, Morel MA, de Vries T, Onuma Y, Farooq V, Serruys PW, Banning AP. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. Eur Heart J 2017;38:3124-34. [PMID: 29020367 DOI: 10.1093/eurheartj/ehx512] [Cited by in F6Publishing: 108] [Reference Citation Analysis]
67 Zwart B, Godschalk TC, Kelder JC, Ten Berg JM. High risk of stent thrombosis in the first 6 months after coronary stenting: Do not discontinue clopidogrel early after ACS. J Interv Cardiol 2017;30:421-6. [PMID: 28836297 DOI: 10.1111/joic.12413] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
68 Abhyankar A, Sandhu MS, Polavarapu RS. Twelve-month comparative analysis of clinical outcomes using biodegradable polymer-coated everolimus-eluting stents versus durable polymer-coated everolimus-eluting stents in all-comer patients. Indian Heart J. 2019;71:149-154. [PMID: 31280828 DOI: 10.1016/j.ihj.2019.04.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Kuramitsu S, Sonoda S, Shinozaki T, Jinnouch H, Muraoka Y, Domei T, Hyodo M, Shirai S, Ando K, Otsuji Y. Impact of lesion complexity on long-term vascular response to cobalt-chromium everolimus-eluting stent: five-year follow-up optical coherence tomography study. Heart Vessels 2018;33:341-50. [PMID: 29051975 DOI: 10.1007/s00380-017-1068-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
70 Park D, Ahn J, Park H, Yun S, Kang D, Lee PH, Kim Y, Lim D, Rha S, Park G, Gwon H, Kim H, Chae I, Jang Y, Jeong M, Tahk S, Seung KB, Park S; On behalf of the PRECOMBAT Investigators. Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow-Up of the PRECOMBAT Trial. Circulation 2020;141:1437-46. [DOI: 10.1161/circulationaha.120.046039] [Cited by in Crossref: 51] [Cited by in F6Publishing: 6] [Article Influence: 25.5] [Reference Citation Analysis]
71 Doshi R, Shah J, Jauhar V, Decter D, Jauhar R, Meraj P. Comparison of drug eluting stents (DESs) and bare metal stents (BMSs) with STEMI: who received BMS in the era of 2nd generation DES? Heart Lung 2018;47:231-6. [PMID: 29544863 DOI: 10.1016/j.hrtlng.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
72 Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA; Writing Committee Members. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021:S0735-1097(21)06158-1. [PMID: 34895950 DOI: 10.1016/j.jacc.2021.09.006] [Cited by in Crossref: 80] [Cited by in F6Publishing: 51] [Article Influence: 80.0] [Reference Citation Analysis]
73 Cui K, Liu H, Yuan F, Xu F, Zhang M, Zhang M, Wang W, Zhang D, Tian J, Lyu S, Dou K. Coronary artery bypass graft surgery versus stenting for patients with chronic kidney disease and complex coronary artery disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 2021;12:2040622321990273. [PMID: 35154627 DOI: 10.1177/2040622321990273] [Reference Citation Analysis]
74 Benedetto U, Caputo M, Vohra H, Bryan A, Angelini GD. State of the art in coronary revascularization: Everolimus eluting stents versus multiple arterial grafting. International Journal of Cardiology 2016;219:345-9. [DOI: 10.1016/j.ijcard.2016.06.059] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
75 Gori T, Polimeni A, Indolfi C, Räber L, Adriaenssens T, Münzel T. Predictors of stent thrombosis and their implications for clinical practice. Nat Rev Cardiol 2019;16:243-56. [DOI: 10.1038/s41569-018-0118-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
76 Radu MD, Engstrøm T. Casting light on coronary evaginations: different mechanisms in different coronary devices? Eur Heart J 2016;37:2050-4. [PMID: 26612580 DOI: 10.1093/eurheartj/ehv623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Zhu P, Zhou X, Zhang C, Li H, Zhang Z, Song Z. Safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer drug-eluting stents: a meta-analysis of randomized trials. BMC Cardiovasc Disord 2018;18:170. [PMID: 30111289 DOI: 10.1186/s12872-018-0902-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
78 Ploumen EH, von Birgelen C. Novel DES aims at full thromboresistance: Another promising player on the field? Cardiovasc Revasc Med 2021:S1553-8389(21)00565-0. [PMID: 34391680 DOI: 10.1016/j.carrev.2021.07.029] [Reference Citation Analysis]
79 He C, Ma YL, Wang CS, Jiang L, Zhang JH, Yao Y, Tang XF, Xu B, Gao RL, Yuan JQ. Long-term Outcomes of Primary Percutaneous Coronary Intervention with Second-generation Drug-eluting Stents in ST-elevation Myocardial Infarction Patients Caused by Very Late Stent Thrombosis. Chin Med J (Engl) 2017;130:929-35. [PMID: 28397722 DOI: 10.4103/0366-6999.204111] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
80 Rizik DG, Hermiller JB, Kereiakes DJ. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials: Randomized Trial Evidence for Absorb. Cathet Cardiovasc Intervent 2016;88:21-30. [DOI: 10.1002/ccd.26810] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
81 Ma YL, Tang XF, Yao Y, Xu N, Song Y, Jiang P, Xu JJ, Wang HH, Jiang L, Liu R, Zhao XY, Chen J, Gao Z, Qiao SB, Yang YJ, Gao RL, Xu B, Yuan JQ. Comparison of Efficacy and Safety between First- and Second-Generation Drug-Eluting Stents in Patients with Acute Coronary Syndrome. Chin Med J (Engl) 2018;131:1397-405. [PMID: 29893356 DOI: 10.4103/0366-6999.233959] [Reference Citation Analysis]
82 Cheng Y, Ferrone M, Wang Q, Perkins LEL, McGregor J, Redfors B, Zhou Z, Rapoza R, Conditt GB, Finn A, Virmani R, Kaluza GL, Granada JF. Impact of Coronary Atherosclerosis on Bioresorbable Vascular Scaffold Resorption and Vessel Wall Integration. JACC Basic Transl Sci 2020;5:619-29. [PMID: 32613147 DOI: 10.1016/j.jacbts.2020.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Jinnouchi H, Otsuka F, Sato Y, Bhoite RR, Sakamoto A, Torii S, Yahagi K, Cornelissen A, Mori M, Kawakami R, Kolodgie FD, Virmani R, Finn AV. Healthy Strut Coverage After Coronary Stent Implantation: An Ex Vivo Human Autopsy Study. Circ Cardiovasc Interv 2020;13:e008869. [PMID: 32338525 DOI: 10.1161/CIRCINTERVENTIONS.119.008869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Grines CL, Harjai KJ, Schreiber TL. Percutaneous Coronary Intervention: 2015 in Review: PCI: 2015 IN REVIEW. Journal of Interventional Cardiology 2016;29:11-26. [DOI: 10.1111/joic.12272] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
85 Lee MS, Kang J, Park KW, Cho H, Lee HS, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Percutaneous Treatment of Unprotected Left Main Disease With Thin-Strut Durable-Polymer or Early Generation Thicker-Strutted and Coated Bioabsorbable-Polymer Drug-Eluting Stents in a Large-Scale Registry. Cardiovasc Revasc Med 2021;32:43-9. [PMID: 33446435 DOI: 10.1016/j.carrev.2020.12.034] [Reference Citation Analysis]
86 Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO. 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial. J Am Coll Cardiol. 2017;70:2852-2862. [PMID: 29100702 DOI: 10.1016/j.jacc.2017.10.010] [Cited by in Crossref: 129] [Cited by in F6Publishing: 92] [Article Influence: 25.8] [Reference Citation Analysis]
87 Lee PH, Kang SH, Han S, Ahn J, Bae JS, Lee CH, Kang S, Lee S, Kim Y, Lee CW, Park S, Park D, Park S. Generalizability of EXCEL and NOBLE results to a large registry population with unprotected left main coronary artery disease. Coronary Artery Disease 2017;28:675-82. [DOI: 10.1097/mca.0000000000000543] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
88 Benedetto U, Gaudino M, Ng C, Biondi-Zoccai G, D'Ascenzo F, Frati G, Girardi LN, Angelini GD, Taggart DP. Coronary surgery is superior to drug eluting stents in multivessel disease. Systematic review and meta-analysis of contemporary randomized controlled trials. Int J Cardiol 2016;210:19-24. [PMID: 26922707 DOI: 10.1016/j.ijcard.2016.02.090] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
89 Didier R, Morice MC, Barragan P, Noryani AAL, Noor HA, Majwal T, Hovasse T, Castellant P, Schneeberger M, Maillard L, Bressolette E, Wojcik J, Delarche N, Blanchard D, Jouve B, Ormezzano O, Paganelli F, Levy G, Sainsous J, Carrie D, Furber A, Berlan J, Darremont O, Le Breton H, Lyuycx-Bore A, Gommeaux A, Cassat C, Kermarrec A, Cazaux P, Druelles P, Dauphin R, Armengaud J, Dupouy P, Champagnac D, Ohlmann P, Ben Amer H, Kiss RG, Ungi I, Gilard M. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). JACC Cardiovasc Interv 2017;10:1202-10. [PMID: 28641840 DOI: 10.1016/j.jcin.2017.03.049] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 8.8] [Reference Citation Analysis]
90 Russian Society of Cardiology (RSC) .. 2020 Clinical practice guidelines for Stable coronary artery disease. Russ J Cardiol 2020;25:4076. [DOI: 10.15829/29/1560-4071-2020-4076] [Cited by in Crossref: 36] [Cited by in F6Publishing: 8] [Article Influence: 18.0] [Reference Citation Analysis]
91 Jeger R, Pfisterer M, Pfister O, Rickenbacher P, Handke M, Gilgen N, Coslovsky M, Kaiser C. First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study. Postepy Kardiol Interwencyjnej 2016;12:314-20. [PMID: 27980544 DOI: 10.5114/aic.2016.63630] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
92 Ali ZA, Karimi Galougahi K, Shlofmitz R, Maehara A, Mintz GS, Abizaid A, Chamié D, Hill J, Serruys PW, Onuma Y, Stone GW. Imaging-guided pre-dilatation, stenting, post-dilatation: a protocolized approach highlighting the importance of intravascular imaging for implantation of bioresorbable scaffolds. Expert Review of Cardiovascular Therapy 2018;16:431-40. [DOI: 10.1080/14779072.2018.1473034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
93 Benedetto U, Taggart DP, Sousa-Uva M, Biondi-Zoccai G, Di Franco A, Ohmes LB, Rahouma M, Kamel M, Caputo M, Girardi LN, Angelini GD, Gaudino M. New-generation stents compared with coronary bypass surgery for unprotected left main disease: A word of caution. J Thorac Cardiovasc Surg 2018;155:2013-2019.e16. [PMID: 29338862 DOI: 10.1016/j.jtcvs.2017.11.066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
94 Fazel R, Vilain KA, Cohen DJ, Yeh RW. Weighing the potential late benefits versus early hazard associated with bioresorbable vascular scaffolds in percutaneous coronary interventions: a Markov decision analytic model. Coron Artery Dis 2020;31:230-6. [PMID: 31658137 DOI: 10.1097/MCA.0000000000000810] [Reference Citation Analysis]
95 Rocha RV, Tam DY, Fremes SE. Commentary: Minimally invasive direct coronary artery bypass for isolated left anterior descending lesions: A welcomed innovation. J Thorac Cardiovasc Surg 2020:S0022-5223(20)31310-6. [PMID: 32653281 DOI: 10.1016/j.jtcvs.2020.05.075] [Reference Citation Analysis]
96 Mahtta D, Mahmoud AN, Mojadidi MK, Elgendy IY. Intravascular Ultrasound‐Guided Percutaneous Coronary Intervention: An Updated Review. Cardiovascular Innovations and Applications 2018;3:127-36. [DOI: 10.15212/cvia.2017.0029] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 Shreenivas S, Kereiakes DJ, Ellis SG, Gao R, Kimura T, Onuma Y, Piard-ruster K, Zhang Y, Koo K, Vu M, Serruys PW, Stone GW. Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males. JACC: Cardiovascular Interventions 2017;10:1881-90. [DOI: 10.1016/j.jcin.2017.07.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
98 Guedeney P, Mesnier J, Sorrentino S, Abcha F, Zeitouni M, Lattuca B, Silvain J, De Rosa S, Indolfi C, Collet JP, Kerneis M, Montalescot G. Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med 2020;9:E680. [PMID: 32138287 DOI: 10.3390/jcm9030680] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
99 Elia E, Montecucco F, Portincasa P, Sahebkar A, Mollazadeh H, Carbone F. Update on pathological platelet activation in coronary thrombosis. J Cell Physiol 2019;234:2121-33. [PMID: 30317596 DOI: 10.1002/jcp.27575] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
100 Hahn J, Song YB, Oh J, Cho D, Lee JB, Doh J, Kim S, Jeong J, Bae J, Kim B, Cho JH, Suh I, Kim D, Park H, Park J, Choi WG, Lee WS, Kim J, Choi KH, Park TK, Lee JM, Yang JH, Choi J, Choi S, Gwon H, Gwon H, Hahn J, Song YB, Park TK, Lee JM, Yang JH, Choi J, Choi S, Lee J, Choi WG, Bae J, Park HS, Hwang J, Hur S, Rha S, Cho D, Cho SC, Kang WY, Lim S, Lee JB, Kim MH, Cha KS, Choi RK, Chae I, Oh J, Jang WJ, Park YH, Chun WJ, Kim S, Cho JH, Suh I, Park J, Choi JW, Kim B, Doh J, Kim D, Jeong MH, Kang SH, Lee WS, Park H, Jeong J, Ahn K. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. The Lancet 2018;391:1274-84. [DOI: 10.1016/s0140-6736(18)30493-8] [Cited by in Crossref: 135] [Cited by in F6Publishing: 47] [Article Influence: 33.8] [Reference Citation Analysis]
101 Picard F, Pighi M, de Hemptinne Q, Airaksinen J, Vinco G, de Pommereau A, Biancari F, Varenne O. Comparison of the biodegradable polymer everolimus-eluting stent with contemporary drug-eluting stents: A systematic review and meta-analysis. International Journal of Cardiology 2019;278:51-6. [DOI: 10.1016/j.ijcard.2018.11.113] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
102 Lemmert ME, van Mieghem NM, van Geuns RJ, Diletti R, van Bommel RJ, van Domburg RT, de Jaegere PP, Regar E, Zijlstra F, Boersma E, Daemen J. The Promus Premier everolimus-eluting platinum chromium stent with durable polymer evaluated in a real world all-comer population in Rotterdam cardiology hospital (the P-SEARCH registry). Int J Cardiol 2017;240:103-7. [PMID: 28385356 DOI: 10.1016/j.ijcard.2017.03.054] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
103 Kang DY, Lee CH, Lee PH, Ahn JM, Lee SW, Kim YH, Park SW, Nam CW, Choi YS, Rha SW, Cho JH, Kim W, Her SH, Jeong MH, Yang JY, Lee BK, Park HS, Park DW, Park SJ. Comparison of Resolute zotarolimus-eluting and Xience everolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES VI trial. Coron Artery Dis 2019;30:59-66. [PMID: 30507632 DOI: 10.1097/MCA.0000000000000680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
104 Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, Cheong WF, Jones-McMeans J, Su X, Zhang Z, Serruys PW. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet 2016;387:1277-89. [PMID: 26825231 DOI: 10.1016/S0140-6736(15)01039-9] [Cited by in Crossref: 196] [Cited by in F6Publishing: 45] [Article Influence: 32.7] [Reference Citation Analysis]
105 Plakht Y, Abu Eid A, Gilutz H, Shiyovich A. Trends of Cardiovascular Risk Factors in Patients With Acute Myocardial Infarction: Soroka Acute Myocardial Infarction II (SAMI II) Project. Angiology 2019;70:530-8. [PMID: 30518230 DOI: 10.1177/0003319718816479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
106 Lee CH, Kang DY, Han M, Hur SH, Rha SW, Her SH, Seung KB, Kim KS, Lee PH, Ahn JM, Lee SW, Park SW, Park DW, Park SJ; IRIS-DES Registry Investigators. Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients. Int J Cardiol 2019;282:17-23. [PMID: 30745256 DOI: 10.1016/j.ijcard.2019.01.108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
107 Capodanno D. Very late outcomes of drug-eluting stents: the 'catch-down' phenomenon. Eur Heart J 2016;37:3396-8. [PMID: 27651441 DOI: 10.1093/eurheartj/ehw398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
108 Prasitlumkum N, Cheungpasitporn W, Sato R, Thangjui S, Thongprayoon C, Kewcharoen J, Bathini T, Vallabhajosyula S, Ratanapo S, Chokesuwattanaskul R. Comparison of coronary artery bypass graft versus drug-eluting stents in dialysis patients: an updated systemic review and meta-analysis. J Cardiovasc Med (Hagerstown) 2021;22:285-96. [PMID: 33633044 DOI: 10.2459/JCM.0000000000001167] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Lu R, Tang F, Zhang Y, Zhu X, Zhu S, Wang G, Jiang Y, Fan Z. Comparison of Drug-Eluting and Bare Metal Stents in Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis. J Am Heart Assoc 2016;5:e003990. [PMID: 27821401 DOI: 10.1161/JAHA.116.003990] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
110 Xue H, Luo Z, Brown T, Beier S. Design of Self-Expanding Auxetic Stents Using Topology Optimization. Front Bioeng Biotechnol 2020;8:736. [PMID: 32766219 DOI: 10.3389/fbioe.2020.00736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
111 Plakht Y, Gilutz H, Shiyovich A. Temporal trends in acute myocardial infarction: What about survival of hospital survivors? Disparities between STEMI & NSTEMI remain. Soroka acute myocardial infarction II (SAMI-II) project. Int J Cardiol 2016;203:1073-81. [PMID: 26638057 DOI: 10.1016/j.ijcard.2015.11.072] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
112 Wang TKM, Kasargod C, Chan D, Cicovic S, Dimalapang E, Webster M, Nunn C, Devlin G, El-Jack S, Fisher N, Simmonds M, Kneale B, Smyth D, Williams M, Kerr A, Somaratne J. Diagnostic coronary angiography and percutaneous coronary intervention practices in New Zealand: The All New Zealand Acute Coronary Syndrome-Quality Improvement CathPCI registry 3-year study (ANZACS-QI 37). Int J Cardiol 2020;312:37-41. [PMID: 32151441 DOI: 10.1016/j.ijcard.2020.02.063] [Reference Citation Analysis]
113 Mahtta D, Elgendy AY, Elgendy IY, Mahmoud AN, Tobis JM, Mojadidi MK. Intravascular Ultrasound for Guidance and Optimization of Percutaneous Coronary Intervention. Interv Cardiol Clin 2018;7:315-28. [PMID: 29983144 DOI: 10.1016/j.iccl.2018.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
114 Lee S, Choi D, Suh Y, Hong S, Ahn C, Kim J, Kim B, Ko Y, Choi D, Park E, Jang Y, Nam C, Hong M. Long-Term Clinical Outcomes Between Biodegradable and Durable Polymer Drug-Eluting Stents: A Nationwide Cohort Study. Front Cardiovasc Med 2022;9:873114. [DOI: 10.3389/fcvm.2022.873114] [Reference Citation Analysis]
115 Ndunda P, Vindhyal MR, Muutu T, Fanari Z. Clinical Outcomes of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Stent Versus Standard Drug-Eluting Coronary Stents: A Meta-Analysis. Cardiovascular Revascularization Medicine 2020;21:213-21. [DOI: 10.1016/j.carrev.2019.04.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
116 Sabaté M, Windecker S, Iñiguez A, Okkels-Jensen L, Cequier A, Brugaletta S, Hofma SH, Räber L, Christiansen EH, Suttorp M, Pilgrim T, Anne van Es G, Sotomi Y, García-García HM, Onuma Y, Serruys PW. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J 2016;37:229-40. [PMID: 26405232 DOI: 10.1093/eurheartj/ehv500] [Cited by in Crossref: 152] [Cited by in F6Publishing: 97] [Article Influence: 21.7] [Reference Citation Analysis]
117 Capodanno D. Revisiting the Network of Drug-Eluting Stent Trials: Bioresorbable Scaffolds Enter the Arena. JACC Cardiovasc Interv 2016;9:1213-5. [PMID: 27262863 DOI: 10.1016/j.jcin.2016.04.010] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
118 Sato Y, Jinnouchi H, Kolodgie FD, Cheng Q, Janifer C, Kutyna M, Sakamoto A, Cornelissen A, Mori M, Kawakami R, Kawai K, Fernandez R, Ghosh SKB, Romero ME, Perkins LEL, Virmani R, Finn AV. Acute thrombogenicity of fluoropolymer coated stents versus competitive drug-eluting stents under single antiplatelet therapy. Int J Cardiol 2021;338:42-9. [PMID: 34174338 DOI: 10.1016/j.ijcard.2021.06.034] [Reference Citation Analysis]
119 Bavry AA, Park K. Drug-Eluting Stents: Capable of Saving Lives in Dialysis Patients? J Am Coll Cardiol 2016;67:1470-1. [PMID: 27012408 DOI: 10.1016/j.jacc.2015.10.105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
120 Krackhardt F, Kočka V, Waliszewski MW, Utech A, Lustermann M, Hudec M, Studenčan M, Schwefer M, Yu J, Jeong MH, Ahn T, Wan Ahmad WA, Boxberger M, Schneider A, Leschke M. Polymer-free sirolimus-eluting stents in a large-scale all-comers population. Open Heart 2017;4:e000592. [PMID: 28761678 DOI: 10.1136/openhrt-2017-000592] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
121 Partida RA, Yeh RW. Contemporary Drug-Eluting Stent Platforms: Design, Safety, and Clinical Efficacy. Interv Cardiol Clin 2016;5:331-47. [PMID: 28582031 DOI: 10.1016/j.iccl.2016.02.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
122 Torres-flores G, Gonzalez-horta A, Vega-cantu YI, Rodriguez C, Rodriguez-garcia A. Preparation and Characterization of Liposomal Everolimus by Thin-Film Hydration Technique. Advances in Polymer Technology 2020;2020:1-9. [DOI: 10.1155/2020/5462949] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
123 Hong SJ, Kim JS, Hong SJ, Lim DS, Lee SY, Yun KH, Park JK, Kang WC, Kim YH, Yoon HJ, Won H, Nam CM, Ahn CM, Kim BK, Ko YG, Choi D, Jang Y, Hong MK; One-Month DAPT Investigators. 1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial. JACC Cardiovasc Interv 2021;14:1801-11. [PMID: 34332946 DOI: 10.1016/j.jcin.2021.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Stone GW. DAPT Duration After Coronary Stenting: Assessing Risk-Benefit Tradeoffs in Individual Patients. J Am Coll Cardiol 2016;67:2503-5. [PMID: 27230045 DOI: 10.1016/j.jacc.2016.03.531] [Reference Citation Analysis]
125 Elgendy IY, Mahmoud AN, Elgendy AY, Bavry AA. Outcomes With Intravascular Ultrasound-Guided Stent Implantation: A Meta-Analysis of Randomized Trials in the Era of Drug-Eluting Stents. Circ Cardiovasc Interv 2016;9. [DOI: 10.1161/circinterventions.116.003700] [Cited by in Crossref: 59] [Cited by in F6Publishing: 21] [Article Influence: 9.8] [Reference Citation Analysis]
126 Neupane S, Khawaja O, Edla S, Singh H, Othman H, Bossone E, Yamasaki H, Rosman HS, Eggebrecht H, Mehta RH. Meta-analysis of drug eluting stents compared with bare metal stents in high bleeding risk patients undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv 2019;94:98-104. [DOI: 10.1002/ccd.28045] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
127 Jiang W, Zhao W, Zhou T, Wang L, Qiu T. A Review on Manufacturing and Post-Processing Technology of Vascular Stents. Micromachines 2022;13:140. [DOI: 10.3390/mi13010140] [Reference Citation Analysis]
128 Kwon O, Lee J, Ahn J, Kang S, Lee S, Kim Y, Lee CW, Park S, Park D, Park S; for the IRIS‐DES Registry Investigators. Clinical outcomes of contemporary drug‐eluting stents in patients with and without diabetes mellitus: Multigroup propensity‐score analysis using data from stent‐specific, multicenter, prospective registries. Catheter Cardiovasc Interv 2020;96:243-52. [DOI: 10.1002/ccd.28462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
129 Verdoia M, Khedi E, Suryapranata H, De Luca G. Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials. Rev Esp Cardiol (Engl Ed) 2021;74:140-8. [PMID: 32482558 DOI: 10.1016/j.rec.2020.03.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Pocock SJ, Clayton TC, Stone GW. Challenging Issues in Clinical Trial Design. Journal of the American College of Cardiology 2015;66:2886-98. [DOI: 10.1016/j.jacc.2015.10.051] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
131 Yabe T, Toda M, Nakanishi R, Saito D, Watanabe I, Okubo R, Amano H, Ikeda T. Same or Different Drug-Eluting Stent Re-Implantation for Drug-Eluting Stent Restenosis: An Assessment Including Second-Generation Drug-Eluting Stents. J Interv Cardiol 2016;29:311-8. [PMID: 27245125 DOI: 10.1111/joic.12299] [Reference Citation Analysis]
132 Chichareon P, Katagiri Y, Asano T, Takahashi K, Kogame N, Modolo R, Tenekecioglu E, Chang C, Tomaniak M, Kukreja N, Wykrzykowska JJ, Piek JJ, Serruys PW, Onuma Y. Mechanical properties and performances of contemporary drug-eluting stent: focus on the metallic backbone. Expert Review of Medical Devices 2019;16:211-28. [DOI: 10.1080/17434440.2019.1573142] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
133 Mahtta D, Elgendy IY. Everolimus-eluting bioresorbable vascular scaffolds: learning from the past to improve the future. Minerva Cardioangiol 2019;67:288-305. [PMID: 30895764 DOI: 10.23736/S0026-4725.19.04900-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
134 Galløe AM, Kelbæk H, Thuesen L, Hansen HS, Ravkilde J, Hansen PR, Christiansen EH, Abildgaard U, Stephansen G, Lassen JF, Engstrøm T, Jensen JS, Jeppesen JL, Bligaard N, Bligaard N, Thuesen L, Kelbæk H, Thayssen P, Aarøe J, Hansen PR, Lassen JF, Saunamäki K, Junker A, Ravkilde J, Abildgaard U, Tilsted HH, Engstrøm T, Jensen JS, Bøtker HE, Galatius S, Larsen CT, Kristensen SD, Krusell LR, Abildstrøm SZ, Christiansen EH, Meng M, Okkels L, Stephansen G, Jeppesen JL, Galløe AM. 10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. Journal of the American College of Cardiology 2017;69:616-24. [DOI: 10.1016/j.jacc.2016.11.055] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 9.2] [Reference Citation Analysis]
135 Rinfret S, Baron SJ, Cohen DJ. Percutaneous Coronary Intervention. Journal of the American College of Cardiology 2015;65:2508-10. [DOI: 10.1016/j.jacc.2015.04.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
136 Kuramitsu S, Sonoda S, Ando K, Otake H, Natsuaki M, Anai R, Honda Y, Kadota K, Kobayashi Y, Kimura T. Drug-eluting stent thrombosis: current and future perspectives. Cardiovasc Interv Ther 2021;36:158-68. [PMID: 33439454 DOI: 10.1007/s12928-021-00754-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
137 Vale N, Madeira S, Almeida M, Raposo L, Freitas P, Castro M, Rodrigues G, Oliveira A, Brito J, Leal S, de Araújo Gonçalves P, Mesquita Gabriel H, Campante Teles R, Seabra Gomes R. Ten-year survival of patients undergoing coronary angioplasty with first-generation sirolimus-eluting stents and bare-metal stents. Rev Port Cardiol (Engl Ed) 2020;39:639-47. [PMID: 33139170 DOI: 10.1016/j.repc.2020.06.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
138 Fu L, Zhu W, Huang L, Hu J, Ma J, Lip GYH, Hong K. Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials. Am J Cardiovasc Drugs 2019;19:37-47. [PMID: 30182350 DOI: 10.1007/s40256-018-0299-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
139 Canfield J, Totary-Jain H. 40 Years of Percutaneous Coronary Intervention: History and Future Directions. J Pers Med 2018;8:E33. [PMID: 30275411 DOI: 10.3390/jpm8040033] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 6.8] [Reference Citation Analysis]
140 Zarogoulidis P, Sardeli C, Konstantinou F, Sapalidis K. Conventional Versus Therapeutic Stents for Airway Malignancies: Novel Local Therapies Underway. EBioMedicine 2018;33:10-1. [PMID: 30049382 DOI: 10.1016/j.ebiom.2018.06.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
141 Guedeney P, Collet JP. Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines. J Clin Med 2020;9:E3474. [PMID: 33126578 DOI: 10.3390/jcm9113474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
142 Didier R, Gaglia MA Jr, Lipinski MJ, Koifman E, Kiramijyan S, Negi S, Gai J, Torguson R, Pichard AD, Waksman R. Comparison of Baseline Characteristics and Inhospital Outcomes of Patients and Use of Bare Metal Versus Drug-Eluting Stents During Percutaneous Coronary Intervention 2005 to 2015 at a Single Tertiary Hospital. Am J Cardiol 2017;119:1324-30. [PMID: 28258727 DOI: 10.1016/j.amjcard.2017.01.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
143 Gijsen F, Katagiri Y, Barlis P, Bourantas C, Collet C, Coskun U, Daemen J, Dijkstra J, Edelman E, Evans P, van der Heiden K, Hose R, Koo BK, Krams R, Marsden A, Migliavacca F, Onuma Y, Ooi A, Poon E, Samady H, Stone P, Takahashi K, Tang D, Thondapu V, Tenekecioglu E, Timmins L, Torii R, Wentzel J, Serruys P. Expert recommendations on the assessment of wall shear stress in human coronary arteries: existing methodologies, technical considerations, and clinical applications. Eur Heart J 2019;40:3421-33. [PMID: 31566246 DOI: 10.1093/eurheartj/ehz551] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 23.0] [Reference Citation Analysis]
144 Chen YL, Fan J, Chen G, Cao L, Lu L, Xu Y, Yin Y. Polymer-free drug-eluting stents versus permanent polymer drug-eluting stents: An updated meta-analysis. Medicine (Baltimore) 2019;98:e15217. [PMID: 30985722 DOI: 10.1097/MD.0000000000015217] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
145 Ferko N, Ferrante G, Hasegawa JT, Schikorr T, Soleas IM, Hernandez JB, Sabaté M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius S, Cequier A, Eberli F, de Belder A, Serruys PW, Valgimigli M. Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials. Catheter Cardiovasc Interv 2017;89:994-1002. [PMID: 27527508 DOI: 10.1002/ccd.26700] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
146 Shao QY, Wang ZJ, Ma XT, Lin XZ, Pan L, Zhou YJ. Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2021;21:574. [PMID: 34852763 DOI: 10.1186/s12872-021-02384-w] [Reference Citation Analysis]
147 Varenhorst C, Lindholm M, Sarno G, Olivecrona G, Jensen U, Nilsson J, Carlsson J, James S, Lagerqvist B. Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents. Clin Res Cardiol 2018;107:816-23. [PMID: 29667015 DOI: 10.1007/s00392-018-1252-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
148 Asano T, Serruys PW, Collet C, Miyazaki Y, Takahashi K, Chichareon P, Katagiri Y, Modolo R, Tenekecioglu E, Morel M, Garg S, Wykrzykowska J, Piek JJ, Sabate M, Morice M, Chevalier B, Windecker S, Onuma Y. Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. European Heart Journal 2018;39:3381-9. [DOI: 10.1093/eurheartj/ehy436] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
149 Wang TKM, Grey C, Jiang Y, Selak V, Bullen C, Jackson RT, Kerr AJ. Trends in cardiovascular outcomes after acute coronary syndrome in New Zealand 2006-2016. Heart 2020:heartjnl-2020-316891. [PMID: 32826288 DOI: 10.1136/heartjnl-2020-316891] [Reference Citation Analysis]
150 Elgendy IY, Gad MM, Elgendy AY, Mahmoud A, Mahmoud AN, Cuesta J, Rivero F, Alfonso F. Clinical and Angiographic Outcomes With Drug-Coated Balloons for De Novo Coronary Lesions: A Meta-Analysis of Randomized Clinical Trials. J Am Heart Assoc 2020;9:e016224. [PMID: 32410493 DOI: 10.1161/JAHA.120.016224] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
151 Bavishi C, Chugh Y, Kimura T, Natsuaki M, Kaiser C, Gordon P, Aronow HD, Abbott JD. Biodegradable polymer drug-eluting stent vs. contemporary durable polymer drug-eluting stents in patients with diabetes: a meta-analysis of randomized controlled trials. Eur Heart J Qual Care Clin Outcomes 2020;6:81-8. [PMID: 31228186 DOI: 10.1093/ehjqcco/qcz031] [Reference Citation Analysis]
152 Park D, Park S. Percutaneous Coronary Intervention of Left Main Disease: Pre- and Post-EXCEL (Evaluation of XIENCE Everolimus Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) and NOBLE (Nordic-Baltic-British Left Main Revascularization Study) Era. Circ: Cardiovascular Interventions 2017;10. [DOI: 10.1161/circinterventions.117.004792] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
153 Neumann JT, Goßling A, Sörensen NA, Blankenberg S, Magnussen C, Westermann D. Sex-Specific Outcomes in Patients with Acute Coronary Syndrome. J Clin Med 2020;9:E2124. [PMID: 32640661 DOI: 10.3390/jcm9072124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
154 Tomberli B, Mattesini A, Baldereschi GI, Di Mario C. Breve historia de los stents coronarios. Revista Española de Cardiología 2018;71:312-9. [DOI: 10.1016/j.recesp.2017.11.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
155 Alfonso F, Cuesta J, Bastante T, Rivero F, García-Guimaraes M, Alvarado T, Benedicto A, Cortese B, Byrne R, Kastrati A. Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion? J Thorac Dis 2016;8:E417-23. [PMID: 27293870 DOI: 10.21037/jtd.2016.03.75] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
156 Montone RA, Niccoli G, De Marco F, Minelli S, D’ascenzo F, Testa L, Bedogni F, Crea F. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials. Circulation 2017;135:2145-54. [DOI: 10.1161/circulationaha.117.028479] [Cited by in Crossref: 36] [Cited by in F6Publishing: 6] [Article Influence: 7.2] [Reference Citation Analysis]
157 Anadol R, Gori T, Jünger M, Krüger-genge A, Jung F. The mechanisms of late scaffold thrombosis. CH 2017;67:343-6. [DOI: 10.3233/ch-179214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
158 Patted SV, Patted AS, Turiya PK, Thakkar AS. Clinical Outcomes of World's Thinnest (50 μmr) Strut Biodegradable Polymer Coated Everolimus-Eluting Coronary Stent System in Real-World Patients. Cardiol Res 2018;9:370-7. [PMID: 30627288 DOI: 10.14740/cr800] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
159 Mester A. Imaging Bioresorbable Vascular Scaffolds – at the Border between Science and Technology. Journal of Interdisciplinary Medicine 2018;3:131-3. [DOI: 10.2478/jim-2018-0036] [Reference Citation Analysis]
160 Pilgrim T, Heg D, Tal K, Erne P, Radovanovic D, Windecker S, Jüni P; AMIS Plus Investigators. Age- and Gender-related Disparities in Primary Percutaneous Coronary Interventions for Acute ST-segment elevation Myocardial Infarction. PLoS One 2015;10:e0137047. [PMID: 26352574 DOI: 10.1371/journal.pone.0137047] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
161 Torrado J, Buckley L, Durán A, Trujillo P, Toldo S, Valle Raleigh J, Abbate A, Biondi-zoccai G, Guzmán LA. Restenosis, Stent Thrombosis, and Bleeding Complications. Journal of the American College of Cardiology 2018;71:1676-95. [DOI: 10.1016/j.jacc.2018.02.023] [Cited by in Crossref: 83] [Cited by in F6Publishing: 57] [Article Influence: 20.8] [Reference Citation Analysis]
162 Collet C, Asano T, Miyazaki Y, Tenekecioglu E, Katagiri Y, Sotomi Y, Cavalcante R, de Winter RJ, Kimura T, Gao R. Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2017;38:2559-2566. [PMID: 28430908 DOI: 10.1093/eurheartj/ehx155] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
163 Guedeney P, Claessen BE, Kalkman DN, Aquino M, Sorrentino S, Giustino G, Farhan S, Vogel B, Sartori S, Montalescot G, Sweeny J, Kovacic JC, Krishnan P, Barman N, Dangas G, Kini A, Baber U, Sharma S, Mehran R. Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol 2019;73:2401-9. [PMID: 31097159 DOI: 10.1016/j.jacc.2019.01.077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
164 Gayle J, Mahapatro A. Magnesium Based Biodegradable Metallic Implant Materials: Corrosion Control and Evaluation of Surface Coatings. ICMS 2019;9:3-27. [DOI: 10.2174/2352094909666190228113315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
165 Jundt MC, Takahashi EA, Harmsen WS, Misra S. Restenosis Rates After Drug-Eluting Stent Treatment for Stenotic Small-Diameter Renal Arteries. Cardiovasc Intervent Radiol 2019;42:1293-301. [PMID: 31267151 DOI: 10.1007/s00270-019-02264-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
166 Postma W, Fabris E, Van der Ent M, Hermanides R, Buszman P, Von Birgelen C C, Cook S, Wedel H, De Luca G, Delewi R, Zijlstra F, Kedhi E. Resolute zotarolimus‐eluting stent in ST‐elevation myocardial infarction (resolute‐STEMI): A prespecified prospective register from the DAPT‐STEMI trial. Catheter Cardiovasc Interv 2020;95:706-10. [DOI: 10.1002/ccd.28376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
167 Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019;321:2414-27. [PMID: 31237644 DOI: 10.1001/jama.2019.8145] [Cited by in Crossref: 391] [Cited by in F6Publishing: 293] [Article Influence: 130.3] [Reference Citation Analysis]
168 Takeji Y, Shiomi H, Morimoto T, Yoshikawa Y, Taniguchi R, Mutsumura-Nakano Y, Yamamoto K, Yamaji K, Tazaki J, Suwa S, Inoko M, Takeda T, Shirotani M, Ehara N, Ishii K, Inada T, Onodera T, Shinoda E, Yamamoto T, Tamura T, Nakatsuma K, Sakamoto H, Ando K, Soga Y, Furukawa Y, Sato Y, Nakagawa Y, Kadota K, Komiya T, Minatoya K, Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-2 and the CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators. Demographics, practice patterns and long-term outcomes of patients with non-ST-segment elevation acute coronary syndrome in the past two decades: the CREDO-Kyoto Cohort-2 and Cohort-3. BMJ Open 2021;11:e044329. [PMID: 33619198 DOI: 10.1136/bmjopen-2020-044329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Verdoia M, Kedhi E, Suryapranata H, Galasso G, Dudek D, De Luca G. Poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: A meta-analysis of 11 randomized trials. Catheter Cardiovasc Interv 2020;96:813-24. [PMID: 31730255 DOI: 10.1002/ccd.28594] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
170 Chen C, Chen J, Wu W, Shi Y, Jin L, Petrini L, Shen L, Yuan G, Ding W, Ge J, Edelman ER, Migliavacca F. In vivo and in vitro evaluation of a biodegradable magnesium vascular stent designed by shape optimization strategy. Biomaterials 2019;221:119414. [PMID: 31419654 DOI: 10.1016/j.biomaterials.2019.119414] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
171 Rao J, Pan Bei H, Yang Y, Liu Y, Lin H, Zhao X. Nitric Oxide-Producing Cardiovascular Stent Coatings for Prevention of Thrombosis and Restenosis. Front Bioeng Biotechnol 2020;8:578. [PMID: 32671029 DOI: 10.3389/fbioe.2020.00578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
172 Boudoulas KD, Triposciadis F, Geleris P, Boudoulas H. Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management. Prog Cardiovasc Dis 2016;58:676-92. [PMID: 27091673 DOI: 10.1016/j.pcad.2016.04.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
173 Dayan V, Myers P. Comparing apples and oranges and adding inches to meters: Is this the way to conduct rigorous meta-analyses of PCI versus CABG in left main coronary disease? Am Heart J 2020;229:180-1. [PMID: 33187626 DOI: 10.1016/j.ahj.2020.08.011] [Reference Citation Analysis]
174 Verdoia M, Camaro C, Kedhi E, Marcolongo M, Suryapranata H, De Luca G. Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues. Cardiovasc Ther 2020;2020:6495036. [PMID: 32328172 DOI: 10.1155/2020/6495036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Cui K, Lyu S, Song X, Liu H, Yuan F, Xu F, Zhang M, Wang W, Zhang M, Zhang D, Tian J. Drug-Eluting Stent Versus Coronary Artery Bypass Grafting for Diabetic Patients With Multivessel and/or Left Main Coronary Artery Disease: A Meta-Analysis. Angiology 2019;70:765-73. [PMID: 30995117 DOI: 10.1177/0003319719839885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
176 Brener SJ, Tarantini G, Leon MB, Serruys PW, Smits PC, von Birgelen C, Crowley A, Ben-Yehuda O, Stone GW. Cardiovascular and Noncardiovascular Death After Percutaneous Coronary Intervention: Insights From 32 882 Patients Enrolled in 21 Randomized Trials. Circ Cardiovasc Interv 2018;11:e006488. [PMID: 30006331 DOI: 10.1161/CIRCINTERVENTIONS.118.006488] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
177 Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, Im ES, Jeong JO, Cho BR, Oh SK, Yun KH, Cho DK, Lee JY, Koh YY, Bae JW, Choi JW, Lee WS, Yoon HJ, Lee SU, Cho JH, Choi WG, Rha SW, Lee JM, Park TK, Yang JH, Choi JH, Choi SH, Lee SH, Gwon HC; SMART-CHOICE Investigators. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA 2019;321:2428-37. [PMID: 31237645 DOI: 10.1001/jama.2019.8146] [Cited by in Crossref: 271] [Cited by in F6Publishing: 218] [Article Influence: 90.3] [Reference Citation Analysis]
178 Roule V, Lemaitre A, Pommier W, Bignon M, Sabatier R, Blanchart K, Beygui F. Safety and efficacy of very short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy in older patients undergoing percutaneous coronary intervention: meta-analysis of randomised controlled trials. Age Ageing 2021;50:1102-7. [PMID: 33755049 DOI: 10.1093/ageing/afab047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
179 Partow-Navid R, Prasitlumkum N, Mukherjee A, Varadarajan P, Pai RG. Management of ST Elevation Myocardial Infarction (STEMI) in Different Settings. Int J Angiol 2021;30:67-75. [PMID: 34025097 DOI: 10.1055/s-0041-1723944] [Reference Citation Analysis]
180 Ohno Y, Yamaji K, Kohsaka S, Inohara T, Amano T, Ishii H, Kadota K, Nakamura M, Nakazawa G, Yoshimachi F, Ikari Y; J-PCI Registry Investigators. Incidence and In-Hospital Outcomes of Patients Presenting With Stent Thrombosis (from the Japanese Nationwide Percutaneous Coronary Intervention Registry). Am J Cardiol 2020;125:720-6. [PMID: 31889525 DOI: 10.1016/j.amjcard.2019.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
181 Palmerini T, Serruys P, Kappetein AP, Genereux P, Riva DD, Reggiani LB, Christiansen EH, Holm NR, Thuesen L, Makikallio T, Morice MC, Ahn JM, Park SJ, Thiele H, Boudriot E, Sabatino M, Romanello M, Biondi-Zoccai G, Cavalcante R, Sabik JF, Stone GW. Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients. Am Heart J 2017;190:54-63. [PMID: 28760214 DOI: 10.1016/j.ahj.2017.05.005] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 11.8] [Reference Citation Analysis]
182 Zeller T, Brechtel K, Meyer D, Noory E, Beschorner U, Albrecht T. Six-Month Outcomes From the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions. J Endovasc Ther 2020;27:683-90. [DOI: 10.1177/1526602820941811] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
183 Kereiakes DJ, Windecker S, Jobe RL, Mehta SR, Sarembock IJ, Feldman RL, Stein B, Dubois C, Grady T, Saito S, Kimura T, Underwood P, Allocco DJ, Meredith IT. Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents: Final 5-Year Results of the EVOLVE II Randomized Trial. Circ: Cardiovascular Interventions 2019;12. [DOI: 10.1161/circinterventions.119.008152] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 7.3] [Reference Citation Analysis]
184 Nappi F, Nenna A, Larobina D, Martuscelli G, Singh SSA, Chello M, Ambrosio L. The Use of Bioactive Polymers for Intervention and Tissue Engineering: The New Frontier for Cardiovascular Therapy. Polymers (Basel) 2021;13:446. [PMID: 33573282 DOI: 10.3390/polym13030446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
185 Bittl JA. Everolimus-Eluting Coronary Stents for Patients With Chronic Kidney Disease: What Explains the Magic? J Am Coll Cardiol 2015;66:1221-3. [PMID: 26361151 DOI: 10.1016/j.jacc.2015.07.034] [Reference Citation Analysis]
186 Bjerking LH, Hansen KW, Sørensen R, Prescott E, Biering-Sørensen T, Jeger R, Kaiser C, Pfisterer M, Galatius S. Drug-eluting stents in large coronary vessels improve both safety and efficacy compared with bare-metal stents in women: a pooled analysis of the BASKET-PROVE I and II trials. Open Heart 2019;6:e000986. [PMID: 31217999 DOI: 10.1136/openhrt-2018-000986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
187 Yan YF, Jiang L, Zhang MD, Li XH, Nie MX, Feng TT, Zhao X, Wang LY, Zhao QM. Can Platforms Affect the Safety and Efficacy of Drug-Eluting Stents in the Era of Biodegradable Polymers?: A Meta-Analysis of 34,850 Randomized Individuals. PLoS One 2016;11:e0151259. [PMID: 27032086 DOI: 10.1371/journal.pone.0151259] [Reference Citation Analysis]
188 Cho MS, Park DW. Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice. Korean J Intern Med 2017;32:769-79. [PMID: 28823143 DOI: 10.3904/kjim.2016.391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
189 Deharo P, Quilici J, Camoin-jau L, Johnson TW, Bassez C, Bonnet G, Fernandez M, Ibrahim M, Suchon P, Verdier V, Fourcade L, Morange PE, Bonnet JL, Alessi MC, Cuisset T. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity. JACC: Cardiovascular Interventions 2017;10:2560-70. [DOI: 10.1016/j.jcin.2017.08.044] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
190 Alkhalil M, Conlon CP, Ashrafian H, Choudhury RP. Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World J Clin Cases 2017; 5(2): 40-45 [PMID: 28255546 DOI: 10.12998/wjcc.v5.i2.40] [Reference Citation Analysis]
191 Elgendy IY, Mahmoud AN, Elgendy AY, Bavry AA. Does the Baseline Coronary Lesion Length Impact Outcomes With IVUS-Guided Percutaneous Coronary Intervention? Journal of the American College of Cardiology 2016;68:569-70. [DOI: 10.1016/j.jacc.2016.05.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
192 Mizutani Y, Ishikawa T, Nakamura H, Yamada K, Shimura M, Kondo Y, Ukaji T, Aoki H, Hisauchi I, Itabashi Y, Nakahara S, Taguchi I. A Propensity Score-Matched Comparison of Midterm Outcomes Between Drug-Coated Balloons and Drug-Eluting Stents for Patients with Acute Coronary Syndrome: A Single-Center Study. Int Heart J . [DOI: 10.1536/ihj.21-576] [Reference Citation Analysis]
193 Seidler T. [Coronary interventions : Current developments for improved long-term results]. Internist (Berl) 2016;57:832-43. [PMID: 27506215 DOI: 10.1007/s00108-016-0111-1] [Reference Citation Analysis]
194 Tu Q, Zhao X, Liu S, Li X, Zhang Q, Yu H, Xiong K, Huang N, Yang Z. Spatiotemporal dual-delivery of therapeutic gas and growth factor for prevention of vascular stent thrombosis and restenosis. Applied Materials Today 2020;19:100546. [DOI: 10.1016/j.apmt.2019.100546] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
195 Chevalier B. Primary PCI. Journal of the American College of Cardiology 2019;74:2585-7. [DOI: 10.1016/j.jacc.2019.09.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
196 Wang F, Herrmann J. In Reply II-A Differing Opinion on Primary Percutaneous Coronary Intervention in Patients Who Have Had Cancer: Stent Choice in Onco-cardiology Revisited. Mayo Clin Proc 2017;92:1317-8. [PMID: 28778272 DOI: 10.1016/j.mayocp.2017.05.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
197 Sun Y, Liu X, Xu Y. The optimal duration of dual antiplatelet therapy in East Asian patients undergoing percutaneous coronary intervention with drug-eluting stents: a meta-analysis of randomized trials. Coron Artery Dis 2021;32:119-30. [PMID: 32639246 DOI: 10.1097/MCA.0000000000000921] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
198 Jang JY, Shin DH, Kim JS, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, Park KW, Gwon HC, Kim HS, Jang Y. Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome. PLoS One 2018;13:e0207386. [PMID: 30475845 DOI: 10.1371/journal.pone.0207386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
199 Poder TG, Erraji J, Coulibaly LP, Koffi K. Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: Systematic review and cost-benefit analysis. PLoS One 2017;12:e0177476. [PMID: 28498849 DOI: 10.1371/journal.pone.0177476] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
200 Yin SH, Xu P, Wang B, Lu Y, Wu QY, Zhou ML, Wu JR, Cai JJ, Sun X, Yuan H. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ 2019;365:l2222. [PMID: 31253632 DOI: 10.1136/bmj.l2222] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 13.7] [Reference Citation Analysis]
201 Joa H, Blažević T, Grojer C, Zeller I, Heiss EH, Atanasov AG, Feldler I, Gruzdaitis P, Czaloun C, Proksch P, Messner B, Bernhard D, Dirsch VM. Tylophorine reduces protein biosynthesis and rapidly decreases cyclin D1, inhibiting vascular smooth muscle cell proliferation in vitro and in organ culture. Phytomedicine 2019;60:152938. [PMID: 31078367 DOI: 10.1016/j.phymed.2019.152938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
202 Qian C, Feng H, Cao J, Zhang G, Wang Y. Intravascular ultrasound guidance in drug-eluting stents implantation: a meta-analysis and trial sequential analysis of randomized controlled trials. Oncotarget 2017;8:59387-96. [PMID: 28938644 DOI: 10.18632/oncotarget.19613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
203 Kosmidou I, Leon MB, Zhang Y, Serruys PW, von Birgelen C, Smits PC, Ben-yehuda O, Redfors B, Madhavan MV, Maehara A, Mehran R, Stone GW. Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention. Journal of the American College of Cardiology 2020;75:1631-40. [DOI: 10.1016/j.jacc.2020.01.056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
204 Dehghani P. Bioresorbable Polymers and Stent Devices. Curr Treat Options Cardiovasc Med 2017;19:12. [PMID: 28275942 DOI: 10.1007/s11936-017-0510-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
205 Luo L, Fu M, Li Y, Chen Z, Yu J, Luo J, Hu S, Tu L, Xu X. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention. Clin Cardiol 2020;43:235-41. [PMID: 31777973 DOI: 10.1002/clc.23305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
206 Madhavan MV, Stone GW. Adverse events beyond 1 year after percutaneous coronary intervention. Current Opinion in Cardiology 2020;35:687-96. [DOI: 10.1097/hco.0000000000000792] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
207 Shah R, Jovin IS, Latham SB, Hesterberg K, Heckle MR, Rashid A, Vetrovec GW. A comprehensive meta-analysis of randomized controlled trials comparing drug-eluting stents with bare-metal stents in saphenous vein graft interventions. Catheter Cardiovasc Interv 2018;92:1229-36. [PMID: 30051628 DOI: 10.1002/ccd.27687] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
208 Choe JC, Park JH, Lee HC, Park TS, Ahn J, Park JS, Lee HW, Oh JH, Choi JH, Cha KS, Yim C, Jeon S. Histopathologic response after hydrophilic polyethylene glycol-coating stent and hydrophobic octadecylthiol-coating stent implantations in porcine coronary restenosis model. J Mater Sci Mater Med 2020;31:122. [PMID: 33247775 DOI: 10.1007/s10856-020-06452-z] [Reference Citation Analysis]
209 Palmerini T, Stone GW. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence. Eur Heart J 2016;37:353-64. [DOI: 10.1093/eurheartj/ehv712] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 7.7] [Reference Citation Analysis]
210 Mattke S, Hanson M, Bentele M, Kandzari DE. Cost and Mortality Implications of Lower Event Rates After Implantation of an Ultrathin-Strut Coronary Stent Compared With a Thin-Strut Stent Over Four Years. Cardiovasc Revasc Med 2020;21:835-42. [PMID: 31954661 DOI: 10.1016/j.carrev.2019.12.018] [Reference Citation Analysis]
211 Kandzari DE, Amjadi N, Caputo C, Rowe SK, Chen H, Williams J, Tamboli HP, Underwood PL, Allocco DJ, Meredith IT. Final 5-Year Results in Unselected Patients Implanted With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study). Am J Cardiol 2019;123:1765-71. [PMID: 30926144 DOI: 10.1016/j.amjcard.2019.02.041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
212 Vidula MK, Secemsky EA, Yeh RW. Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician. Progress in Cardiovascular Diseases 2018;60:491-9. [DOI: 10.1016/j.pcad.2018.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
213 Abdelaziz HK, Abuomara HZ, Ali MH, Eichhofer J, Patel B, Saad M. Routine use of optical coherence tomography in bioresorbable vascular scaffold implantation: insights on technique optimization and long-term outcomes. Coron Artery Dis 2019;30:263-9. [PMID: 30883433 DOI: 10.1097/MCA.0000000000000736] [Reference Citation Analysis]
214 Qiu H, Tu Q, Gao P, Li X, Maitz MF, Xiong K, Huang N, Yang Z. Phenolic-amine chemistry mediated synergistic modification with polyphenols and thrombin inhibitor for combating the thrombosis and inflammation of cardiovascular stents. Biomaterials 2021;269:120626. [PMID: 33418199 DOI: 10.1016/j.biomaterials.2020.120626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
215 Vale N, Madeira S, Almeida M, Raposo L, Freitas P, Castro M, Rodrigues G, Oliveira A, Brito J, Leal S, de Araújo Gonçalves P, Mesquita Gabriel H, Campante Teles R, Seabra Gomes R. Ten-year survival of patients undergoing coronary angioplasty with first-generation sirolimus-eluting stents and bare-metal stents. Revista Portuguesa de Cardiologia (English Edition) 2020;39:639-47. [DOI: 10.1016/j.repce.2020.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
216 Wu H, Jan S, Chang S, Huang C, Lin M. Correlation Between Smoking Paradox and Heart Rhythm Outcomes in Patients With Coronary Artery Disease Receiving Percutaneous Coronary Intervention. Front Cardiovasc Med 2022;9:803650. [DOI: 10.3389/fcvm.2022.803650] [Reference Citation Analysis]
217 Elgendy IY, Mahmoud AN, Elgendy AY, Mojadidi MK, Elbadawi A, Eshtehardi P, Pérez-vizcayno MJ, Wayangankar SA, Jneid H, David Anderson R, Alfonso F. Drug-Eluting Balloons Versus Everolimus-Eluting Stents for In-Stent Restenosis: A Meta-Analysis of Randomized Trials. Cardiovascular Revascularization Medicine 2019;20:612-8. [DOI: 10.1016/j.carrev.2018.08.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
218 Li L, Wang L, Zhai CJ, Mou YR, Wang JH, Cui LQ. Clinical utility of intravascular ultrasonography-guided therapy in a small-vessel coronary lesion associated with Type 2 diabetes mellitus. Anatol J Cardiol 2019;22:68-76. [PMID: 31375651 DOI: 10.14744/AnatolJCardiol.2019.77009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
219 Zhang F, Zhang Q, Li X, Huang N, Zhao X, Yang Z. Mussel-inspired dopamine-CuII coatings for sustained in situ generation of nitric oxide for prevention of stent thrombosis and restenosis. Biomaterials 2019;194:117-29. [DOI: 10.1016/j.biomaterials.2018.12.020] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 17.0] [Reference Citation Analysis]
220 Antich-Isern P, Caro-Barri J, Aparicio-Blanco J. The combination of medical devices and medicinal products revisited from the new European legal framework. Int J Pharm 2021;607:120992. [PMID: 34390808 DOI: 10.1016/j.ijpharm.2021.120992] [Reference Citation Analysis]
221 Jinnouchi H, Sakakura K, Yanase T, Ugata Y, Tsukui T, Taniguchi Y, Yamamoto K, Seguchi M, Wada H, Fujita H. Impact of stent edge dissection detected by optical coherence tomography after current-generation drug-eluting stent implantation. PLoS One 2021;16:e0259693. [PMID: 34735528 DOI: 10.1371/journal.pone.0259693] [Reference Citation Analysis]
222 Nakamura N, Torii S, Tsuchiya H, Nakano A, Oikawa Y, Yajima J, Nakamura S, Nakano M, Masuda N, Ohta H, Yumoto K, Natsumeda M, Ijichi T, Ikari Y, Nakazawa G. Formation of Calcified Nodule as a Cause of Early In-Stent Restenosis in Patients Undergoing Dialysis. J Am Heart Assoc 2020;9:e016595. [PMID: 32964759 DOI: 10.1161/JAHA.120.016595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
223 Kheiri B, Osman M, Abdalla A, Haykal T, Chahine A, Gwinn M, Ahmed S, Hassan M, Bachuwa G, Bhatt DL. Drug-Eluting Versus Bare-Metal Stents in Older Patients: A Meta-Analysis of Randomized Controlled Trials. Cardiovasc Revasc Med 2019;20:744-51. [PMID: 30446398 DOI: 10.1016/j.carrev.2018.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
224 Wang R, Wu S, Gamal A, Gao C, Hara H, Kawashima H, Ono M, van Geuns RJ, Vranckx P, Windecker S, Onuma Y, Serruys PW, Garg S. Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond. Eur Heart J Cardiovasc Pharmacother 2021:pvab035. [PMID: 33930107 DOI: 10.1093/ehjcvp/pvab035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
225 Basaraba JE, Barry AR. Short- versus standard-term dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: A meta-analysis. J Cardiol 2017;69:353-8. [PMID: 27590413 DOI: 10.1016/j.jjcc.2016.07.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
226 Jang WJ, Ahn SG, Song YB, Choi S, Chun WJ, Oh JH, Cho SW, Kim BS, Yoon JH, Koo B, Yu CW, Jang YS, Tahk S, Kim H, Gwon H, Lee SY, Hahn J. Benefit of Prolonged Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stent for Coronary Bifurcation Lesions: Results From the Coronary Bifurcation Stenting Registry II. Circ: Cardiovascular Interventions 2018;11. [DOI: 10.1161/circinterventions.117.005849] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
227 Takahara M, Kitahara H, Nishi T, Miura K, Miyayama T, Sugimoto K, Nakayama T, Fujimoto Y, Kobayashi Y. Very early tissue coverage after drug-eluting stent implantation: an optical coherence tomography study. Int J Cardiovasc Imaging 2017;33:25-30. [PMID: 27601229 DOI: 10.1007/s10554-016-0972-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
228 Verdoia M, Kedhi E, Suryapranata H, Galasso G, Dudek D, De Luca G. Polymer-Free vs. Polymer-Coated Drug-Eluting Stents for the Treatment of Coronary Artery Disease: A Meta-Analysis of 16 Randomized Trials. Cardiovasc Revasc Med 2020;21:745-53. [PMID: 31669109 DOI: 10.1016/j.carrev.2019.10.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
229 Iannaccone M, D'ascenzo F, Templin C, Omedè P, Montefusco A, Guagliumi G, Serruys PW, Di Mario C, Kochman J, Quadri G, Biondi-zoccai G, Lüscher TF, Moretti C, D'amico M, Gaita F, Stone GW. Optical coherence tomography evaluation of intermediate-term healing of different stent types: systemic review and meta-analysis. Eur Heart J Cardiovasc Imaging 2017;18:159-66. [DOI: 10.1093/ehjci/jew070] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
230 Verdoia M, Barbieri L, Kedhi E, Suryapranata H, De Luca G. Percutaneous Versus Surgical Revascularization for Left Main or Multivessel Coronary Artery Disease: Results From a Large-Scale Meta-Analysis in the Era of Drug-Eluting Stents. Angiology 2018;69:812-24. [DOI: 10.1177/0003319718768656] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
231 Tzifa A, Mylonas KS, Halapas A. Recurrent coarctation in Williams syndrome: novel approach of drug-eluting stent implantation. Cardiol Young 2020;30:294-7. [PMID: 31941559 DOI: 10.1017/S1047951119003202] [Reference Citation Analysis]
232 Azzalini L, Stone GW. Percutaneous Coronary Intervention or Surgery for Unprotected Left Main Disease: EXCEL Trial at 5 Years. Interv Cardiol Clin 2020;9:419-32. [PMID: 32921366 DOI: 10.1016/j.iccl.2020.05.002] [Reference Citation Analysis]
233 Kogame N, Guimarães PO, Modolo R, De Martino F, Tinoco J, Ribeiro EE, Kawashima H, Ono M, Hara H, Wang R, Cavalcante R, Moulin B, Falcão BA, Leite RS, de Almeida Sampaio FB, Morais GR, Meireles GC, Campos CM, Onuma Y, Serruys PW, Lemos PA. Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD. JACC: Cardiovascular Interventions 2020;13:2251-62. [DOI: 10.1016/j.jcin.2020.06.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
234 Spadaccio C, Benedetto U. Coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in the treatment of multivessel coronary disease: quo vadis? -a review of the evidences on coronary artery disease. Ann Cardiothorac Surg 2018;7:506-15. [PMID: 30094215 DOI: 10.21037/acs.2018.05.17] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
235 Jung HW, Lim C, Bae HJ, Lee JH, Lee YJ, Kim JS, Lee SJ, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, Jang Y. Association between in-stent neointimal characteristics and native coronary artery disease progression. PLoS One 2021;16:e0247359. [PMID: 33891606 DOI: 10.1371/journal.pone.0247359] [Reference Citation Analysis]
236 Stone GW, Gao R, Kimura T, Simonton C, Serruys PW. Optimum technique to reduce risk of stent thrombosis – Authors' reply. The Lancet 2016;388:127-8. [DOI: 10.1016/s0140-6736(16)30772-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Franchi F, Rollini F, Park Y, Angiolillo DJ. Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike. Progress in Cardiovascular Diseases 2015;58:267-77. [DOI: 10.1016/j.pcad.2015.08.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
238 Taglieri N, Bruno AG, Ghetti G, Marrozzini C, Saia F, Galié N, Palmerini T. Target Lesion Failure With Current Drug-Eluting Stents: Evidence From a Comprehensive Network Meta-Analysis. JACC Cardiovasc Interv 2020;13:2868-78. [PMID: 33357524 DOI: 10.1016/j.jcin.2020.09.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
239 Kayatta MO, Halkos ME. Reviewing hybrid coronary revascularization: challenges, controversies and opportunities. Expert Rev Cardiovasc Ther 2016;14:821-30. [PMID: 27042753 DOI: 10.1080/14779072.2016.1174576] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
240 Cavalcante R, Sotomi Y, Mancone M, Whan Lee C, Ahn J, Onuma Y, Lemos PA, van Geuns R, Park S, Serruys PW. Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. European Heart Journal 2017;38:1969-77. [DOI: 10.1093/eurheartj/ehx138] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 8.2] [Reference Citation Analysis]
241 Kang S, Chae I, Park J, Lee HS, Kang D, Hwang S, Youn T, Kim H. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds. JACC: Cardiovascular Interventions 2016;9:1203-12. [DOI: 10.1016/j.jcin.2016.03.038] [Cited by in Crossref: 84] [Cited by in F6Publishing: 59] [Article Influence: 14.0] [Reference Citation Analysis]
242 Hwang JK, Lee SH, Song YB, Ahn J, Carriere K, Jang MJ, Park TK, Choi SH, Yang JH, Choi JH, Lee SH, Gwon HC, Hahn JY. Glycemic Control Status After Percutaneous Coronary Intervention and Long-Term Clinical Outcomes in Patients With Type 2 Diabetes Mellitus. Circ Cardiovasc Interv 2017;10:e004157. [PMID: 28373177 DOI: 10.1161/CIRCINTERVENTIONS.116.004157] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
243 Park DW, Ahn JM, Park SJ, Taggart DP. Percutaneous coronary intervention in left main disease: SYNTAX, PRECOMBAT, EXCEL and NOBLE-combined cardiology and cardiac surgery perspective. Ann Cardiothorac Surg 2018;7:521-6. [PMID: 30094217 DOI: 10.21037/acs.2018.04.04] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
244 Lhermusier T, Carrie D, Cayla G, Fajadet J, Sainsous J, Elhadad S, Tarragano F, Chevalier B, Ranc S, Curinier C, Le Breton H, Koning R; FRANCE ABSORB Investigators. Three-year clinical outcomes with the ABSORB bioresorbable vascular scaffold in real life: Insights from the France ABSORB registry. Catheter Cardiovasc Interv 2021;98:511-9. [PMID: 33211387 DOI: 10.1002/ccd.29369] [Reference Citation Analysis]
245 Fan ZG, Tian NL, He SH, Ma GS. Maintained P2Y12 inhibitor monotherapy after shorter-duration of dual antiplatelet therapy in patients undergoing coronary drug-eluting stents implantation: An updated meta-analysis of randomized trials. J Clin Pharm Ther 2022. [PMID: 35218029 DOI: 10.1111/jcpt.13626] [Reference Citation Analysis]
246 Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018;. [PMID: 30165437 DOI: 10.1093/eurheartj/ehy394] [Cited by in Crossref: 1826] [Cited by in F6Publishing: 1379] [Article Influence: 913.0] [Reference Citation Analysis]
247 Kawamoto H, Ruparelia N, Tanaka A, Chieffo A, Latib A, Colombo A. Bioresorbable Scaffolds for the Management of Coronary Bifurcation Lesions. JACC: Cardiovascular Interventions 2016;9:989-1000. [DOI: 10.1016/j.jcin.2016.02.038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
248 Cohen JL, Glickstein JS, Crystal MA. Drug-Coated Balloon Angioplasty: A Novel Treatment for Pulmonary Artery In-Stent Stenosis in a Patient with Williams Syndrome. Pediatr Cardiol 2017;38:1716-21. [DOI: 10.1007/s00246-017-1646-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
249 Lee PH, Kwon O, Ahn J, Lee CH, Kang D, Lee J, Kang S, Lee S, Kim Y, Lee CW, Park S, Park D, Park S. Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease. Journal of the American College of Cardiology 2018;71:832-41. [DOI: 10.1016/j.jacc.2017.12.032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
250 Bonaventura A, Montecucco F, Liberale L. Coronary stenting: A matter of revascularization. World J Cardiol 2017; 9(3): 207-211 [PMID: 28400917 DOI: 10.4330/wjc.v9.i3.207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
251 de Jager TAJ, Dulfer K, Radhoe S, Bergmann MJ, Daemen J, van Domburg RT, Lenzen MJ, Utens EMWJ. Predictive value of depression and anxiety for long-term mortality: differences in outcome between acute coronary syndrome and stable angina pectoris. Int J Cardiol 2018;250:43-8. [PMID: 28992998 DOI: 10.1016/j.ijcard.2017.10.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
252 Mori M, Sakamoto A, Sato Y, Kawakami R, Kawai K, Cornelissen A, Abebe B, Ghosh S, Romero ME, Kolodgie FD, Virmani R, Finn AV. Overcoming challenges in refining the current generation of coronary stents. Expert Rev Cardiovasc Ther 2021;19:1013-28. [PMID: 34860134 DOI: 10.1080/14779072.2021.2013810] [Reference Citation Analysis]
253 Crimi G, Gritti V, Galiffa VA, Scotti V, Leonardi S, Ferrario M, Ferlini M, De Ferrari GM, Oltrona Visconti L, Klersy C. Drug eluting stents are superior to bare metal stents to reduce clinical outcome and stent-related complications in CKD patients, a systematic review, meta-analysis and network meta-analysis. J Interven Cardiol 2018;31:319-29. [DOI: 10.1111/joic.12473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
254 Choi JM, Lee SH, Kang M, Choi JH. Impact of medication adherence to dual antiplatelet therapy on the long-term outcome of drug-eluting or bare-metal stents. PLoS One 2020;15:e0244062. [PMID: 33326492 DOI: 10.1371/journal.pone.0244062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
255 D’ascenzo F, Iannaccone M, Saint-hilary G, Bertaina M, Schulz-schüpke S, Wahn Lee C, Chieffo A, Helft G, Gili S, Barbero U, Biondi Zoccai G, Moretti C, Ugo F, D’amico M, Garbo R, Stone G, Rettegno S, Omedè P, Conrotto F, Templin C, Colombo A, Park S, Kastrati A, Hildick-smith D, Gasparini M, Gaita F. Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients. European Heart Journal 2017;38:3160-72. [DOI: 10.1093/eurheartj/ehx437] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 11.0] [Reference Citation Analysis]
256 Alkhouli M. Coronary Calcifications in Patients Undergoing PCI: The Forgotten Enemy Back in the Spotlight. JACC Cardiovasc Interv 2020;13:1429-31. [PMID: 32553330 DOI: 10.1016/j.jcin.2020.04.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
257 Lemmert ME, Oldroyd K, Barragan P, Lesiak M, Byrne RA, Merkulov E, Daemen J, Onuma Y, Witberg K, van Geuns RJ. Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial. Am Heart J 2017;187:104-11. [PMID: 28454794 DOI: 10.1016/j.ahj.2017.02.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
258 Steg PG, Serruys PW, Abdelghani M, Wijns W. The year in cardiology 2015: coronary intervention. Eur Heart J 2016;37:335-43. [PMID: 26726048 DOI: 10.1093/eurheartj/ehv708] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
259 Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, Hovasse T, Garot P, El Mahmoud R, Spaulding C, Helft G, Diaz Fernandez JF, Brugaletta S, Pinar-bermudez E, Mauri Ferre J, Commeau P, Teiger E, Bogaerts K, Sabate M, Morice M, Sinnaeve PR. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. The Lancet 2018;391:41-50. [DOI: 10.1016/s0140-6736(17)32713-7] [Cited by in Crossref: 190] [Cited by in F6Publishing: 43] [Article Influence: 47.5] [Reference Citation Analysis]
260 Garg A, Rout A, Tayal R, Sharma A, Agrawal S, Kostis JB, Cohen M, Sharma S, Wasty N. Drug-eluting Stents Versus Bare-metal Stents for Saphenous Vein Graft Interventions: A Systematic Review and Meta-analysis of Studies With Longer Follow-up. Curr Probl Cardiol 2021;46:100405. [PMID: 30792045 DOI: 10.1016/j.cpcardiol.2018.12.002] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
261 Lee CW, Park SJ. Stent length and outcomes after drug-eluting stent placement: time to redefine long lesions. Coron Artery Dis 2017;28:452-3. [PMID: 28379856 DOI: 10.1097/MCA.0000000000000493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
262 Jeger RV, Möbius-Winkler S. Stents in saphenous vein grafts. Lancet 2018;391:1967-8. [PMID: 29759511 DOI: 10.1016/S0140-6736(18)30937-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
263 Chen C, Tan J, Wu W, Petrini L, Zhang L, Shi Y, Cattarinuzzi E, Pei J, Huang H, Ding W, Yuan G, Migliavacca F. Modeling and Experimental Studies of Coating Delamination of Biodegradable Magnesium Alloy Cardiovascular Stents. ACS Biomater Sci Eng 2018;4:3864-73. [DOI: 10.1021/acsbiomaterials.8b00700] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
264 Kereiakes DJ, Onuma Y, Serruys PW, Stone GW. Bioresorbable Vascular Scaffolds for Coronary Revascularization. Circulation 2016;134:168-82. [PMID: 27400899 DOI: 10.1161/CIRCULATIONAHA.116.021539] [Cited by in Crossref: 72] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
265 Briede I, Narbute I, Kumsars I, Sondore D, Trushinskis K, Jegere S, Latkovskis G, Strenge K, Rudzitis A, Erglis A. Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data. Postepy Kardiol Interwencyjnej 2018;14:144-8. [PMID: 30008766 DOI: 10.5114/aic.2018.76405] [Reference Citation Analysis]
266 Kee HJ, Lee EJ, Han JC, Kee C. Ahmed implant coated with poly(2-methacryloyloxyethyl phosphorylcholine) inhibits foreign body reactions in rabbit eyes. PLoS One 2021;16:e0252467. [PMID: 34048489 DOI: 10.1371/journal.pone.0252467] [Reference Citation Analysis]
267 Partida RA, Yeh RW. Contemporary Drug-Eluting Stent Platforms: Design, Safety, and Clinical Efficacy. Cardiol Clin 2017;35:281-96. [PMID: 28411902 DOI: 10.1016/j.ccl.2016.12.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
268 Aziz MK, Herrmann J, Marmagkiolis K, Balanescu DV, Donisan T, Pushparaji B, Lin HY, Tomakin G, Hoyt T, Pham M, Dijkstra J, Cilingiroglu M, Lopez-Mattei J, Zaha V, Anderson HV, Feldman MD, Molony DA, Iliescu CA. Coronary Stent Healing in Cancer Patients-An Optical Coherence Tomography Perspective. Front Cardiovasc Med 2021;8:665303. [PMID: 34164440 DOI: 10.3389/fcvm.2021.665303] [Reference Citation Analysis]
269 Hada M, Yonetsu T, Sugiyama T, Kanaji Y, Hoshino M, Usui E, Araki M, Yamaguchi M, Misawa T, Nagamine T, Nogami K, Yasui Y, Hishikari K, Hikita H, Takahashi A, Sasano T, Kakuta T. Vascular Responses to First-Generation Sirolimus-Eluting Stents and Bare-Metal Stents Beyond 10 Years. Circ Rep 2021;3:201-10. [PMID: 33842725 DOI: 10.1253/circrep.CR-21-0025] [Reference Citation Analysis]
270 Mehran R, Giustino G. “Capturing” the Benefits of Dual-Therapy Stent Technology. JACC: Cardiovascular Interventions 2016;9:1135-7. [DOI: 10.1016/j.jcin.2016.03.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
271 Ali ZA, Gao R, Kimura T, Onuma Y, Kereiakes DJ, Ellis SG, Chevalier B, Vu MT, Zhang Z, Simonton CA. Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials. Circulation. 2018;137:464-479. [PMID: 29089314 DOI: 10.1161/circulationaha.117.031843] [Cited by in Crossref: 108] [Cited by in F6Publishing: 19] [Article Influence: 21.6] [Reference Citation Analysis]
272 Mauler-Wittwer S, Garot P. The Biolimus A9-coated BioFreedom stent: from clinical efficacy to real-world evidence. Future Cardiol 2021;17:239-55. [PMID: 32893680 DOI: 10.2217/fca-2020-0069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
273 Luo H, Zhou C, Chi J, Pan S, Lin H, Gao F, Ni T, Meng L, Zhang J, Jiang C, Ji Z, Lv H, Guo H. The Role of Tauroursodeoxycholic Acid on Dedifferentiation of Vascular Smooth Muscle Cells by Modulation of Endoplasmic Reticulum Stress and as an Oral Drug Inhibiting In-Stent Restenosis. Cardiovasc Drugs Ther 2019;33:25-33. [DOI: 10.1007/s10557-018-6844-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
274 Touani FK, Borie M, Azzi F, Trudel D, Noiseux N, Der Sarkissian S, Lerouge S. Pharmacological Preconditioning Improves the Viability and Proangiogenic Paracrine Function of Hydrogel-Encapsulated Mesenchymal Stromal Cells. Stem Cells Int 2021;2021:6663467. [PMID: 34367293 DOI: 10.1155/2021/6663467] [Reference Citation Analysis]
275 Lu W, Zhu Y, Han Z, Sun G, Qin X, Wang Z, Liu G, Xi W, Wang X, Pan L, Qiu C. Short-term outcomes from drug-coated balloon for coronary de novo lesions in large vessels. Journal of Cardiology 2019;73:151-5. [DOI: 10.1016/j.jjcc.2018.07.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
276 Patti G, Micieli G, Cimminiello C, Bolognese L. The Role of Clopidogrel in 2020: A Reappraisal. Cardiovasc Ther 2020;2020:8703627. [PMID: 32284734 DOI: 10.1155/2020/8703627] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
277 Mori H, Gupta A, Torii S, Harari E, Jinnouchi H, Virmani R, Finn AV. Clinical implications of blood-material interaction and drug eluting stent polymers in review. Expert Rev Med Devices 2017;14:707-16. [PMID: 28770625 DOI: 10.1080/17434440.2017.1363646] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
278 De Rosa R, Piscione F, Galasso G, De Servi S, Savonitto S. Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes. J Geriatr Cardiol 2019;16:103-13. [PMID: 30923541 DOI: 10.11909/j.issn.1671-5411.2019.02.006] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
279 Choe JC, Cha KS, Lee JG, Kim J, Shin JY, Ahn J, Park JS, Lee HW, Oh J, Choi JH, Lee HC, Hong TJ, Jeong MH. Long-Term Outcomes of Biodegradable Versus Second-Generation Durable Polymer Drug-Eluting Stent Implantations for Myocardial Infarction. JACC: Cardiovascular Interventions 2020;13:97-111. [DOI: 10.1016/j.jcin.2019.08.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
280 Collet C, Sotomi Y, Cavalcante R, Suwannasom P, Tenekecioglu E, Onuma Y, Serruys PW. Coronary stent thrombosis: what have we learned? J Thorac Dis 2016;8:1398-405. [PMID: 27500366 DOI: 10.21037/jtd.2016.05.69] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
281 Cai JZ, Lu WQ, Xu C, Gu J, You W, Xu T, Gogas BD, Jia HB, Ye F. The association of diabetes mellitus with neointimal formation following deployment of second-generation drug-eluting stents: an optical coherence tomographic study. Coron Artery Dis 2021;32:105-11. [PMID: 33060524 DOI: 10.1097/MCA.0000000000000964] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
282 Cho SC, Park DW, Park SJ. Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting for the Treatment of Left Main Coronary Artery Disease. Korean Circ J 2019;49:369-83. [PMID: 31074210 DOI: 10.4070/kcj.2019.0112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
283 Madhavan MV, Kirtane AJ, Redfors B, Généreux P, Ben-Yehuda O, Palmerini T, Benedetto U, Biondi-Zoccai G, Smits PC, von Birgelen C, Mehran R, McAndrew T, Serruys PW, Leon MB, Pocock SJ, Stone GW. Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. J Am Coll Cardiol 2020;75:590-604. [PMID: 32057373 DOI: 10.1016/j.jacc.2019.11.058] [Cited by in Crossref: 77] [Cited by in F6Publishing: 59] [Article Influence: 38.5] [Reference Citation Analysis]
284 Baron SJ, Lei Y, Chinnakondepalli K, Vilain K, Magnuson EA, Kereiakes DJ, Ellis SG, Stone GW, Cohen DJ; ABSORB III Investigators. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial. JACC Cardiovasc Interv 2017;10:774-82. [PMID: 28427593 DOI: 10.1016/j.jcin.2017.01.022] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
285 Cornelissen A, Guo L, Sakamoto A, Jinnouchi H, Sato Y, Kuntz S, Kawakami R, Mori M, Fernandez R, Fuller D, Gadhoke N, Kolodgie FD, Surve D, Romero ME, Virmani R, Finn AV. Histopathologic and physiologic effect of bifurcation stenting: current status and future prospects. Expert Rev Med Devices 2020;17:189-200. [PMID: 32101062 DOI: 10.1080/17434440.2020.1733410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
286 Shah R, Hesterberg K. Drug-eluting stents versus bare-metal stents for saphenous vein graft interventions. J Thorac Dis 2019;11:S1257-60. [PMID: 31245102 DOI: 10.21037/jtd.2019.02.50] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]